WO2015051302A1 - Compositions et procédés de traitement de cancers - Google Patents

Compositions et procédés de traitement de cancers Download PDF

Info

Publication number
WO2015051302A1
WO2015051302A1 PCT/US2014/059140 US2014059140W WO2015051302A1 WO 2015051302 A1 WO2015051302 A1 WO 2015051302A1 US 2014059140 W US2014059140 W US 2014059140W WO 2015051302 A1 WO2015051302 A1 WO 2015051302A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cancer
lor
lymphoma
klf4
Prior art date
Application number
PCT/US2014/059140
Other languages
English (en)
Inventor
William G. Rice
Original Assignee
Aptose Biosciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptose Biosciences Inc. filed Critical Aptose Biosciences Inc.
Priority to EP14850583.7A priority Critical patent/EP3052102B1/fr
Priority to CN201480064470.2A priority patent/CN105764511B/zh
Priority to DK14850583.7T priority patent/DK3052102T3/da
Priority to ES14850583T priority patent/ES2775579T3/es
Priority to EP19197122.5A priority patent/EP3650023A1/fr
Priority to KR1020167011859A priority patent/KR20160058960A/ko
Priority to JP2016519769A priority patent/JP6946000B2/ja
Publication of WO2015051302A1 publication Critical patent/WO2015051302A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates generally to compositions and methods for treating cancers.
  • MDS Myelodysplasia syndromes
  • MDS myelodysplasia syndromes
  • Some types of MDS are mild and easily managed, while other types are severe and life-threatening.
  • Myelodysplasia syndromes (MDS) are rarely cured; most patients never actually complete treatment.
  • the current treatment of MDS is based on the stage and the mechanism of the disease that predominates the particular phase of the disease process. Bone marrow transplantation has been used in patients with poor prognosis or late-stage MDS. Epstein and Slease, 1985, Surg. Ann. 17: 125.
  • Mild MDS can grow more severe over time. It can also develop into a fast-growing, severe leukemia, acute myelogenous leukemia (AML).
  • AML is a subset of leukemia. It is the most common form of adult leukemia (blood cancer) with a ⁇ 20% survival rate after 5 years and less than 5% if patients are age >65.
  • Current treatments for AML are blunt and harsh chemotherapies (i.e., cytarabine, anthracycliine, etc.) that are not targeted and have limiting off- target toxicities.
  • chemotherapies i.e., cytarabine, anthracycliine, etc.
  • the present invention meets this need and provides compositions and methods for the effective treatment of cancers.
  • the invention provides compositions for treating cancers.
  • the compositions comprise at least one anti-cancer active agent that can modulate the CDX2-KLF4 signaling pathway in a human subject.
  • the anti-cancer agents of the present invention can act through one or more mechanisms. Such mechanisms include, but are not limited to: (1) inhibition of CDX2 activity; (2) induction of KLF4 activity; (3) induction of p21 CDK inhibitor; (4) induction of Gl/S Cell cycle arrest; (5) induction of Caspase 3 enzyme; and (6) induction of apoptosis.
  • the term "activity" of a component in the CDX2-KLF4 signaling pathway can be a parameter at genomic DNA level, transcriptional level, post-transcriptional level, translational level, post- translational level, including, but not limited to gene activity, RNA activity, and protein activity.
  • the gene activity can be gene copy number, gene amplification number, or promoter activity, etc.
  • RNA activity can be mRNA abundance, synthesis rate, and/or stability, etc.
  • Protein activity can be protein abundance, synthesis rate, stability, enzymatic activity, phosphorylation rate, modifications, binding activity, etc.
  • the active agent is a small molecule pharmaceutical compound.
  • the pharmaceutical compound is a 2,4,5-trisubstituted imidazole compound described in US 2007/0123553A1, or 2-indolyl imidazo[4,5-d]phenanthroline compounds described in US 8,148,392, or functional derivatives thereof.
  • the pharmaceutical compound has the structure of formula I:
  • R 1 is methyl, isopropyl, or t-butyl.
  • the pharmaceutical compound is selected from the group consisting of:
  • the pharmaceutical compound has the structure of formula II:
  • the cancer is associated with abnormal activity of the CDX2 - KLF4 signaling pathway in the human subject.
  • one or more components in the CDX2 - KLF4 signaling pathway have abnormal activity when compared to the activity of a control group.
  • the cancer is leukemia/lymohoma.
  • the cancer is myelodysplasia syndromes (MDS).
  • the MDS is high-risk MDS.
  • the cancer is acute myelogenous leukemia (AML).
  • the AML is refractory AML.
  • the AML is elderly AML.
  • the cancer is acute lymphocytic leukemia (ALL).
  • ALL is a pediatric ALL.
  • pediatric ALL is pediatric T-cell ALL or pediatric B-cell ALL.
  • CML chronic myelogenous leukemia
  • the cancer is adult T-cell leukaemia (ATLL).
  • the cancer is caused by human T-lymphotrophic virus type 1.
  • the cancer is lymphoma, gastric cancer, or multiple myeloma.
  • the lymphoma is Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), Burkitts lymphoma, or B-cell lymphoma.
  • the cancer is a combination of any of the cancers described herein.
  • the human subject has one or more symptoms of MDS.
  • the human subject to be treated has an ineffective production of blood cells, such as myeloid blood cells.
  • the human subject has an anemia.
  • the human subject has low blood counts caused by bone marrow failure.
  • the cancer is acute myelogenous leukemia (AML).
  • the AML is refractory AML.
  • the AML is elderly AML.
  • elderly AML patients are those patients who have, or may have AML, with an age above 60.
  • elderly AML patients are in their first relapse.
  • the AML is not elderly AML.
  • non-elderly AML patients are those who have, or may have AML, with an age equal to or below 60.
  • the non- elderly AML patients are in their second relapse.
  • the cancer is acute lymphocytic leukemia (ALL).
  • ALL is a pediatric or child ALL.
  • pediatric or child ALL patients are those patients who have, or may have ALL, with an age under 21.
  • the ALL is not pediatric or child ALL.
  • non-pediatric ALL patients are those who have, or may have ALL, with an age equal to or above 21.
  • an anti-cancer compound of the present invention is administered to a human subject in need as part of a combination therapy.
  • the combination therapy comprises radiotherapy.
  • the combination therapy comprises chemotherapy.
  • an effective amount of an anti-cancer agent or a pharmacologically acceptable salt or solvate thereof of the present invention is administered to the human subject.
  • an effective amount of the anti-cancer agent is effective to treat the cancer or symptoms of the cancer, effective to inhibit cancer cell proliferation, or effective to prevent or reduce severity of a future occurrence of cancer when administered to a subject who is susceptible and/or who may develop a cancer or symptoms of the cancer.
  • the administration of the anti-cancer agent provides statistically significant therapeutic effect or clinical efficacy for treating the cancer.
  • an anti-cancer compound of the present invention is administered with a dosage of about 0.01 to about 200mg.
  • an anti-cancer compound of the present invention is administered with a dosage of about 0.05 to about lOOmg. In some embodiments, an anti-cancer compound of the present invention is administered with a dosage of about 1.0 to about 50 mg. In some embodiments, the daily dosages of the compounds of the present invention typically fall within the range of about 0.01 to about 100 mg/kg of body weight, or within the range of about 20 mg/m2 to about 400 mg/m2 in single or divided dose. In some embodiments, an anti-cancer compound of the present invention is administered once, twice, three times or more per day.
  • the treatment last 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more cycles. In some embodiments, each cycle lasts at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days. In some embodiments, the gap between two cycles is at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more days.
  • the anti-cancer agent is unit dosage form.
  • the cancer to be treated is AML
  • the compound is LOR-253 (a. k. a. APTO-253)
  • the compound is administered with a dosage of about 125 mg/m2.
  • the compound is administered two times per week for four weeks.
  • the invention provides methods for treating a condition associated with abnormal activity of the CDX2 - KLF4 signaling pathway.
  • the condition is associated with abnormal activity of one or more component of the CDX2 - KLF4 signaling pathway, such as CDX2, KLF4, p21 , and/or p53 in a human subject.
  • the condition is associated with abnormal (e.g., lower than normal) level of KLF4 activity.
  • the condition is associated with abnormal (e.g., higher than normal) level of CDX2 activity.
  • the abnormal level of CDX2 is due to a genetic alteration of CDX2.
  • the methods of the present invention further comprise determining the activity of a component in the CDX2 - KLF4 signaling pathway, such as the KLF4 activity and/or CDX2 activity in the human subject before, during, and/or after the treatment. In some embodiments, the methods of the present invention further comprise determining the presence or absence of a genetic alteration of CDX2. [0024] Additional aspects and embodiments of the invention will be apparent from the detailed description that follows.
  • FIG. 1 is a diagram of non-limiting mechanism of how an active agent of the present invention (e.g., formula I, a.k.a. LOR-253 or APTO-253) treats cancer.
  • an active agent of the present invention e.g., formula I, a.k.a. LOR-253 or APTO-253 treats cancer.
  • KLF4 is down regulated, which is essential for accelerated cell proliferation, epithelial-mesenchymal transition (EMT) and metastasis
  • EMT epithelial-mesenchymal transition
  • metastasis in certain hematologic cancers: KLF4 is down regulated, which is essential for leukemogenesis.
  • LOR-253 induces KLF4 expression which in turn inhibits cancer cell proliferation, EMT, and metastasis, and/or triggers apoptosis.
  • FIG. 2 is a diagram that shows non-limiting mechanism of how CDX2 functions in certain cancers and how LOR-253 treats such cancers.
  • the CDX2 gene in normal cells of the hematopoietic system, the CDX2 gene is turned off or expressed at a relatively low level. In certain cancers including AML, CDX2 is turned on or increased, leading to aberrantly expressed CDX2 transcription factor. CDX2 binds to the promoter region of the KLF4 gene and inhibits KLF4 expression, which is an essential step to promote leukemogenesis. LOR-253 induces KLF4 expression which in turn triggers apoptosis of the cancerous leukocytes. [0027] FIG.
  • FIG. 3 is a graphical representation of the effect of LOR-253 on proliferation of a number of cancer cell lines in vitro.
  • Cells of various cancer cell lines were incubated with LOR-253 as described in the Examples, and the cell concentrations of various cell lines for 50% of maximal inhibition of cell proliferation (GI 5 o) by LOR-253 were determined and shown in the figure.
  • FIG. 4 is a graphical representation of the effect of LOR-253 on the expression levels of KLF4 in two cell lines, THP- 1 and HL60.
  • FIG. 5 depicts BD FACSCalibur flow cytometer assay result for THP1 and HL-60 AML cell lines treated with DMSO or LOR-253 (left panel).
  • FIG. 5 also shows that treatment of LOR- 253 results in Gl/S cell cycle arrest in THP1 and HL-60 cell lines (right panel).
  • FIG. 6 depicts a BD FACSCanto flow cytometry acquisition plots for THP-1 cells treated with DMSO, 0.5 or 1 uM of LOR-253.
  • THP-1 cells treated with LOR-253 showed elevated Annexin V staining, indicating induction of apoptosis (Q3: Annexin V+/PI-).
  • FIG. 7 depicts Caspase 3 expression level in THP1 and HL-60 AML cell lines treated with DMSO or LOR-253.
  • FIG. 8 depicts fold change in expression of BAX and BCL2 in THP 1 cells treated with DMSO or 0.5 ⁇ LOR-253
  • FIG. 9 depicts in vivo efficacy of LOR-253 HCL in H226 xenograft model mice. Tumor sizes of H226_xenograft mice treated with LOR-253 HCL or negative control measured on the indicated days are shown.
  • FIG. 10 depicts the pharmacokinetic (PK) in CD-I nude mice treated by LOR-253 at a dosage of 1 , 5, or 15 mg/kg.
  • the serum level of LOR-253 has a dose related increase.
  • FIG. 1 1 depicts the pharmacodynamic (PD) responses in mice treated for 5 consecutive days with 1 , 5, and 15 mg/kg LOR-253.
  • the KLF4 protein level was measured 16 hours after the last dose.
  • FIG. 12 depicts tumor shrinkage in patient with NSCLC (poorly differentiated adenocarcinoma) before the treatment (see the upper panel) and after the treatment (see the lower panel).
  • NSCLC poorly differentiated adenocarcinoma
  • FIG. 13 is a diagram that shows non- limiting mechanism of how silencing KLF4 gene or gene product plays a central role in various heme malignancies.
  • epigenetic methylation of the KLF4 gene relates to adult T-cell lymphoma patients
  • mutations in KLF4 genes or proteins relate to pediatric T-cell ALL patients
  • elevated microRNA-2909 relates to pediatric B-cell ALL patients
  • aberrant expression of CDX2 relates to AML, ALL, and MDS patients, which all lead to silencing of KLF4 activity (including but not limited to expressional and functional activities).
  • Silencing of KLF4 has also been observed in various lymphoma.
  • FIG. 14 is a diagram that shows non-limiting mechanism of how KLF4 gene activity can be silenced by genetic mutations or epigenetic events and how LOR-253/APTO-253 can induce KLF4 expression.
  • epigenetic events include, but are not limited to, DNA hypomethylation or demethylation, aberrant/elevated expression of CDX2 which can lead to increased presence of a demethylase KDM5B in an upstream regulatory region of the klf4 gene, and elevated amount of miR-2909.
  • LOR-253/APTO-253 can induce KLF4 expression by relieving gene silencing caused at least by CDX2/KDM5B and/or other mechanisms
  • FIG. 15 depicts in vivo efficacy of LOR-253 HCL in Kasumi-1 xenograft model mice. Tumor sizes of Kasumi-1 xenograft mice treated with LOR-253 HCL or negative control measured on the indicated days are shown.
  • FIG. 16 depicts body weight measurements on the indicated days of Kasumi-1 tumor- bearing Mice treated with LOR-253 HCL or negative control.
  • FIG. 17 depicts in vivo efficacy of LOR-253 HCL as a single agent or in combination with azacitidine in HL-60 xenograft model mice. Tumor sizes of HL-60 xenograft mice treated with the indicated conditions measured on the indicated days are shown.
  • FIG. 18 and FIG. 19 depict the tumor sizes of individual animals at the beginning (Day 1) and end (Day 19) of the study of FIG. 17, respectively.
  • FIG. 20 depicts in vivo efficacy of LOR-253 HCL in KG-1 xenograft model mice. Tumor sizes of KG-1 xenograft mice treated with LOR-253 HCL or negative control measured on the indicated days are shown.
  • FIG. 21 depicts in vivo efficacy of LOR-253 HCL as a single agent or in combination with azacitidine in THP-1 xenograft model mice. Tumor sizes of THP-1 xenograft mice treated with the indicated conditions measured on the indicated days are shown.
  • a or “an” refers to one or more of that entity; for example, "a gene” refers to one or more genes or at least one gene.
  • a gene refers to one or more genes or at least one gene.
  • the terms “a” (or “an”), “one or more” and “at least one” are used interchangeably herein.
  • reference to “an element” by the indefinite article “a” or “an” does not exclude the possibility that more than one of the elements are present, unless the context clearly requires that there is one and only one of the elements.
  • the invention provides isolated, chimeric, recombinant or synthetic polynucleotide sequences.
  • polynucleotide polynucleotide sequence
  • nucleic acid sequence nucleic acid fragment
  • isolated nucleic acid fragment are used interchangeably herein and encompass DNA, RNA, cDNA, whether single stranded or double stranded, as well as chemical modifications thereof. These terms encompass nucleotide sequences and the like.
  • a polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases.
  • a polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. Nucleotides (usually found in their 5'-monophosphate form) are referred to by a single letter designation as follows: “A” for adenylate or deoxyadenylate (for RNA or DNA, respectively), “C” for cytidylate or deoxycytidylate, "G” for guanylate or deoxyguanylate, "U” for uridylate, "T” for deoxythymidylate, "R” for purines (A or G), “Y” for pyrimidines (C or T), "K” for G or T, “H” for A or C or T, “I” for inosine, and “N” for any nucleotide.
  • the isolated, chimeric, recombinant or synthetic polynucleotide sequences are derived from gene markers of the present invention.
  • the invention also provides proteins or polypeptides.
  • the proteins or polypeptides are isolated, purified, chimeric, recombinant or synthetic.
  • polypeptide or “protein” refers to amino acid polymers of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non- amino acids.
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labelling component. Also included are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, eic), as well as other modifications known in the art. Polypeptides can occur as single chains or associated chains. Polypeptides of the invention can take various forms (e.g.
  • sequences of the proteins or polypeptides are derived from gene markers of the present invention.
  • Single letter amino acid abbreviations used herein have their standard meaning in the art, and all peptide sequences described herein are written according to convention, with the N- terminal end to the left and the C-terminal end to the right.
  • the term "component in the CDX2 - KLF4 signaling pathway” refers to CDX2, KLF4, or other genes, gene products (including but not limited to RNA and protein), or other biological molecules that can modulate the activity of CDX2 and/or KLF4, directly or indirectly, or genes, gene products, or other biological molecules that can be modulated by CDX2 and/or KLF4, directly or indirectly.
  • the modulation can either increase or decrease the activity level of a given gene.
  • Such components include, but are not limited to CDX2, KLF4, KDM5B, miR-2909, p53, p21 , Caspase-3, Annexin V, BAX, BCL2, BCL3, BMP, Wnt, HNF4a, Fgf, Hox, SP 1 , MYC, CCND 1 , AATF, and those described in Scholl et al. ("The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis", J. Clin. Invest. 1 17: 1037-1048 (2007).), Yoon et al.
  • KLF4 negatively regulates (or suppresses) the activity of SP1 , MYC, BCL3, CCND 1 , and AATF, directly or indirectly, while positively regulates the activity of p21.
  • KLF4 negatively regulates the activity of p53 in some cancer types (e.g. breast cancer, as described by Rowland et al., The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol. 2005.
  • FIG. 13 An illustration of some possible effects of silenced KLF4 gene expression or activity on some of the genes modulated by KLF4 can be found in FIG. 13.
  • Some other components in the CDX2 - KLF4 signaling pathway can modulate the expression of KLF4. Examples of such components include, but are not limited to, CDX2, KDM5B (a demethylase), and a miRNA "miR-2909".
  • An illustration of some possible mechanisms of how these KLF4 modulators can affect KLF4 gene expression or activity in various cancer types can be found in FIG. 13 and FIG. 14.
  • a component in the CDX2 - KLF4 signaling pathway can be used as a biomarker according to the methods described herein for treating cancers, especially for treating cancers by an anti-cancer agent of the present invention, such as LOR-253/APTO-253.
  • modulate the CDX2 - KLF4 signaling pathway refers to the process in which one or more component in the CDX2 - KLF4 signaling pathway is modulated by an agent or an event (including a mutation). In some embodiments, such modulation leads to increased, decreased, normalized, and/or stabilized activity of one or more components in the CDX2 - KLF4 signaling pathway.
  • lower alkyl refers to (Ci-C6)alkyl.
  • a lower alkyl includes methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, hexyl, (C3-C6)cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), (C3-C6)cycloalkyl(Ci-C6)alkyl (e.g., cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2- cyclopropylethyl, 2-cyclobutylethyl, 2- cyclopentylethyl, or 2-cyclohexylethyl), (Ci-C6)alkoxy (e.g., methoxy, ethoxy
  • C2-C6alkanoyloxy e.g., acetoxy, propanoyloxy, butanoyloxy, isobutanoyloxy, pentanoyloxy, or hexanoyloxy.
  • a compound described herein or its function derivative can be used according to the present invention.
  • derivative includes derivatives, analogs, prodrugs, and unnatural precursors of a given compound.
  • treatment efficacy and variants thereof are generally indicated by alleviation of one or more signs or symptoms associated with the disease and can be readily determined by one skilled in the art.
  • Treatment efficacy may also refer to the prevention or amelioration of signs and symptoms of toxicities typically associated with standard or non-standard treatments of a disease. Determination of treatment efficacy is usually indication and disease specific and can include any methods known or available in the art for determining that a treatment is providing a beneficial effect to a subject.
  • evidence of treatment efficacy can include but is not limited to general improvements in the overall health of the subject, such as but not limited to enhancement of patient life quality, increase in predicted subject survival rate, decrease in depression, decreasing the severity and/or frequency one or more symptoms resulting from the disease, diminishing the extent of the disease, stabilizing the disease (e.g., preventing or delaying the worsening of the disease), delay or slowing the progression of the disease, ameliorating the disease state, etc.
  • the treatment efficacy is clinical efficacy or statistically significant.
  • treating and “treatment” as used herein refer to an approach for obtaining beneficial or desired results including clinical results, and may include even minimal changes or improvements in one or more measurable markers of the disease or condition being treated.
  • a treatment is usually effective to reduce at least one symptom of a condition, disease, disorder, injury or damage. Exemplary markers of clinical improvement will be apparent to persons skilled in the art.
  • Examples include, but are not limited to, one or more of the following: decreasing the severity and/or frequency one or more symptoms resulting from the disease, diminishing the extent of the disease, stabilizing the disease (e.g., preventing or delaying the worsening of the disease), delay or slowing the progression of the disease, ameliorating the disease state, decreasing the dose of one or more other medications required to treat the disease, and/or increasing the quality of life, etc.
  • prophylaxis refers to preventing or reducing the occurrence or severity of one or more symptoms and/or their underlying cause, for example, prevention of a disease or condition in a subject susceptible to developing a disease or condition (e.g., at a higher risk, as a result of genetic predisposition, environmental factors, predisposing diseases or disorders, or the like).
  • disorder refers to any alteration in the state of the body or one of its organs and/or tissues, interrupting or disturbing the performance of organ function and/or tissue function (e.g., causes organ dysfunction) and or causing a symptom such as discomfort, dysfunction, distress, or even death to a subject afflicted with the disease.
  • pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
  • pharmaceutically acceptable refers to a pharmaceutical carrier or excipient, it is implied that the carrier or excipient has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
  • an effective amount refers to the amount of one or more compounds that renders a desired treatment outcome.
  • An effective amount may be comprised within one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint.
  • terapéuticaally effective amount refers to the level or amount of one or more agents needed to treat a condition, or reduce or prevent injury or damage, optionally without causing significant negative or adverse side effects.
  • a “prophylactically effective amount” refers to an amount of an agent sufficient to prevent or reduce severity of a future disease or condition when administered to a subject who is susceptible and/or who may develop a disease or condition.
  • the term "subject,” and variants thereof as used herein includes any subject that has, is suspected of having, or is at risk for having a disease or condition. Suitable subjects (or patients) include mammals, such as laboratory animals (e.g., mouse, rat, rabbit, guinea pig), farm animals, and domestic animals or pets (e.g., cat, dog). Non-human primates and, preferably, human patients, are included.
  • a subject “at risk” may or may not have detectable disease, and may or may not have displayed detectable disease prior to the diagnostic or treatment methods described herein.
  • “At risk” denotes that a subject has one or more so-called risk factors, which are measurable parameters that correlate with development of a condition described herein, which are described herein.
  • a subject having one or more of these risk factors has a higher probability of developing a condition described herein than a subject without these risk factor(s).
  • One example of such a risk factor is an increase or decrease in a biomarker of the present invention as compared to a clinically normal sample.
  • an "increased” or “decreased” amount or level may include a “statistically significant” amount.
  • the administration of an anticancer agent such as LOR-253 provides "statistically significant" therapeutic effect or clinical efficacy for treating the cancer.
  • such statistically significant therapeutic effect or clinical efficacy includes slower cancer cell proliferation or tumor growth caused by the anti-cancer agent as compared to a control vehicle. A result is typically referred to as statistically significant if it is unlikely to have occurred by chance.
  • the significance level of a test or result relates traditionally to the amount of evidence required to accept that an event is unlikely to have arisen by chance.
  • statistical significance may be defined as the probability of making a decision to reject the null hypothesis when the null hypothesis is actually true (a decision known as a Type I error, or "false positive determination"). This decision is often made using the p-value: if the p-value is less than the significance level, then the null hypothesis is rejected. The smaller the p-value, the more significant the result.
  • Bayes factors may also be utilized to determine statistical significance (see, e.g., Goodman S., Ann Intern Med. 130: 1005-13, 1999).
  • an "increased" or “decreased” amount or level is about l . lx, 1.2x, 1.3x, 1.4x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 6x, 7x, 8x, 9x, lOx, 15x, 20x, 25x, 30x, 40x, or 50x more or less the amount of a predetermined standard, or the amount of a determined time point relative to a previous or earlier timepoint.
  • the statistically significant therapeutic effect is determined based on one or more standards or criteria provided by one or more regulatory agencies in the United States, e.g., FDA or other countries. In other embodiments, the statistically significant therapeutic effect is determined based on results obtained from regulatory agency approved clinical trial set up and/or procedure.
  • the statistically significant therapeutic effect is determined based on a patient population of at least 300, 400, 500, 600, 700, 800, 900, 1000 or 2000. In some embodiments, the statistically significant therapeutic effect is determined based on data obtained from randomized and double blinded clinical trial set up. In some embodiments, the statistically significant therapeutic effect is determined based on data with a p value of less than or equal to about 0.05, 0.04, 0.03, 0.02 or 0.01. In some embodiments, the statistically significant therapeutic effect is determined based on data with a confidence interval greater than or equal to 95%, 96%, 97%, 98% or 99%. In some embodiments, the statistically significant therapeutic effect is determined on approval of Phase III clinical trial of the methods provided by the present invention, e.g., by FDA in the US.
  • the statistically significant therapeutic effect is determined by a randomized double blind clinical trial of a patient population of at least 300 or 350, treated with anti-cancer agents such as LOR-253 in combination with standard care. In some embodiment, the statistically significant therapeutic effect is determined by a randomized clinical trial of a patient population of at least 300 or 350 and using 28 day mortality rate, in-hospital mortality rate, ICU mortality rate, ICU duration, ICU free days, sequential organ failure assessment score (SOFA), relative risk of death, ICU frequency, duration of ventilation, frequency of ventilation, ventilation free days or any combination thereof or any other commonly accepted criteria for sepsis assessment.
  • SOFA sequential organ failure assessment score
  • statistical analysis can include any suitable method permitted by a regulatory agency, e.g., FDA in the US or China or any other country.
  • statistical analysis includes non-stratified analysis, log-rank analysis, e.g., from Kaplan-Meier, Jacobson- Truax, Gulliken-Lord-Novick, Edwards-Nunnally, Hageman-Arrindel and Hierarchical Linear Modeling (HLM) and Cox regression analysis.
  • the phrase “per day” describes an amount administered on those days when an agent is administered.
  • the phrase “per day” does not indicate that an amount is administered every day.
  • phrases "pharmaceutically acceptable salt(s)" includes salts of acidic or basic groups which may be present in a compound.
  • Compounds that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bistosylate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edislyate, estolate, esylate, ethylsuccinate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate,
  • prodrug means compounds that are drug precursors, which following administration, release the drug in vivo via some chemical or physiological process (e.g., a prodrug on being brought to the physiological pH is converted to the desired drug form).
  • Continuous dosing schedule refers to a dosing schedule wherein compound of present invention, or a dosage form comprising said compound, is administered during a treatment period without a rest period.
  • the compound, or a dosage form comprising the compound can be administered, for example, daily, every other day, every third day, every forth day, every fifth day, etc.
  • On a day when compound, or a dosage form comprising the compound is administered it can be administered in a single dose, or in multiple doses throughout the day.
  • Intermittent dosing schedule refers to a dosing schedule that comprises a treatment period and a rest period.
  • compound of present invention, or a dosage form comprising said compound can be administered, for example, daily, or every other day, every third day, every forth day, every fifth day, etc.
  • On a day when compound or a dosage form comprising the compound is administered it can be administered in a single dose, or in multiple doses throughout the day.
  • a compound or a dosage form comprising the compound is not administered.
  • the rest period lasts at least one day, at least two days, at least three days, at least four days, at least five days, at least six days, at least a week, at least 1.5 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least one month, at least two months, at least three months, at least four months, at least five months, at least half year, at least one year, at least two years, or more.
  • the treatment period is typically from about 1 day to 30 days, such as about 10 days to 30 days, for example, about 2, 3 or 4 weeks, and the rest period is typically from 1 to 30 days, such as 3 to 15 days, for example, 1 or 2 weeks.
  • Intermittent dosing regimens can be expressed as treatment period in weeks/rest period in weeks.
  • a 4/1 intermittent dosing schedule refers to an intermittent dosing schedule wherein the treatment period is four weeks and the rest period is one week.
  • a 4/2 intermittent dosing schedule refers to an intermittent dosing schedule wherein the treatment period is four weeks and the rest period is two weeks.
  • a 3/1 intermittent dosing schedule refers to an intermittent dosing schedule wherein the treatment period is three weeks and the rest period is one week.
  • the human subject treated by the anti-cancer agent of the present invention may show complete response or partial response.
  • Complete Response refers to disappearance of all measurable and nonmeasurable symptoms and no appearance of new symptoms in a patient under the treatment.
  • Partial Response refers to at least one measurable and nonmeasurable symptom is significantly reduced, or without appearance of new symptom in a patient under treatment.
  • dosing regimens can be adjusted by one skilled in the art to more conveniently accommodate coordination of the dosing regimens, and additional therapeutic agents, if such adjustments are therapeutically acceptable.
  • C max refers to the maximum plasma concentration
  • t max refers to the time when the C max occurs following administering the dosage
  • AUC refers to area under the plasma concentration-time curve from time zero to infinity
  • tm refers to plasma elimination half- life
  • % CV refers to percent coefficient of variation
  • C( tr0 ugh 24 h) refers to trough plasma concentration at 24 hours after dosing
  • QD indicates once daily.
  • the cancers which can be treated in accordance with one embodiment of the present invention thus include, but are not limited to, leukaemias; adenocarcinomas and carcinomas, including squamous cell carcinomas.
  • Carcinomas are also frequently referred to as "solid tumours," as described above, and examples of commonly occurring solid tumours that can be treated in accordance with the present invention include, but are not limited to, anal cancer, bladder cancer, colon cancer, colorectal cancer, duodenal cancer, gastric (stomach) cancer, lung (non-small cell) cancer, oesophageal cancer, prostate cancer, rectal cancer and small intestine cancer.
  • one embodiment of the present invention provides for the use of a compound of Formula I in the treatment of a cancer selected from the group of leukemia, bladder cancer, lung (non-small cell) cancer, prostate cancer and a cancer of the GI tract, wherein cancers of the GI tract include, but are not limited to, anal cancer, colon cancer, colorectal cancer, duodenal cancer, gastric (stomach) cancer, oesophageal cancer, rectal cancer and small intestine cancer.
  • C m a x refers to the maximum plasma concentration
  • t max refers to the time when the C max occurs following administering the dosage
  • AUC refers to area under the plasma concentration-time curve from time zero to infinity
  • tm refers to plasma elimination half- life
  • % CV refers to percent coefficient of variation
  • Choug h 24 h) refers to trough plasma concentration at 24 hours after dosing
  • QD indicates once daily.
  • leukaemia refers broadly to progressive, malignant diseases of the blood-forming organs. Leukaemia is typically characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow but can also refer to malignant diseases of other blood cells such as erythro leukaemia, which affects immature red blood cells.
  • Leukaemia is generally clinically classified on the basis of (1) the duration and character of the disease— acute or chronic; (2) the type of cell involved— myeloid (myelogenous), lymphoid (lymphogenous) or monocytic, and (3) the increase or non-increase in the number of abnormal cells in the blood— leukaemic or aleukaemic (subleukaemic).
  • Leukaemia includes, for example, acute leukaemia, chronic leukaemia, adult leukaemia, pediatric/child leukaemia, lymphocytic leukemia, myeloid leukemia, acute lymphocytic leukemia (ALL), acute nonlymphocytic leukaemia, chronic lymphocytic leukaemia, acute granulocytic leukaemia, chronic granulocytic leukaemia, acute promyelocytic leukaemia, chronic myelogenous leukemia (CML), T-cell leukaemia, B-cell leukaemia, adult T-cell leukaemia, pediatric T-cell ALL, pediatric B-cell ALL, aleukaemic leukaemia, aleukocythemic leukaemia, basophylic leukaemia, blast cell leukaemia, bovine leukaemia, chronic myelocytic leukaemia, leukaemia cutis, embryonal leukaemia, eosinophilic leukaemia
  • carcinomas refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases.
  • the term “carcinoma” also encompasses adenocarcinomas.
  • Adenocarcinomas are carcinomas that originate in cells that make organs which have glandular (secretory) properties or that originate in cells that line hollow viscera, such as the gastrointestinal tract or bronchial epithelia, and include adenocarcinomas of the lung and prostate.
  • Methods of the present invention can be applied in the treatment of early stage cancers including early neoplasias that may be small, slow growing, localized and/or nonaggressive, for example, with the intent of curing the disease or causing regression of the cancer, as well as in the treatment of intermediate stage and in the treatment of late stage cancers including advanced and/or metastatic and/or aggressive neoplasias, for example, to slow the progression of the disease, to reduce metastasis or to increase the survival of the patient.
  • the combinations may be used in the treatment of low grade cancers, intermediate grade cancers and or high grade cancers.
  • Methods of the present invention can also be used in the treatment of indolent cancers, recurrent cancers including locally recurrent, distantly recurrent and/or refractory cancers (i.e. cancers that have not responded to treatment), metastatic cancers, locally advanced cancers and aggressive cancers.
  • an "advanced" cancer includes locally advanced cancer and metastatic cancer and refers to overt disease in a patient, wherein such overt disease is not amenable to cure by local modalities of treatment, such as surgery or radiotherapy.
  • the term "metastatic cancer” refers to cancer that has spread from one part of the body to another. Advanced cancers may also be unresectable, that is, they have spread to surrounding tissue and cannot be surgically removed.
  • Methods of the present invention can also be used in the treatment of drug resistant cancers, including multidrug resistant tumours. As is known in the art, the resistance of cancer cells to chemotherapy is one of the central problems in the management of cancer.
  • Aggressive cancer refers to a rapidly growing cancer.
  • breast cancer or prostate cancer the term “aggressive cancer” will refer to an advanced cancer that has relapsed within approximately the earlier two-thirds of the spectrum of relapse times for a given cancer, whereas for other types of cancer, nearly all cases present rapidly growing cancers which are considered to be aggressive. The term can thus cover a subsection of a certain cancer type or it may encompass all of other cancer types.
  • the cancer is leukemia/lymohoma. In some embodiments, the cancer is acute myelogenous leukemia (AML). In some embodiments, the cancer is lymphoma, gastric cancer, multiple myeloma, myelodysplastic syndromes, or combinations thereof. In some other embodiments, the cancer is T-cell leukemia, e.g., adult T-cell leukemia associated with epigenetic methylation of KLF4 gene. In some other embodiments, the cancer is ALL, e.g., pediatric ALL. In some other embodiments, the cancer is pediatric T-cell ALL associated with one or more mutations in KLF4 gene or protein.
  • AML acute myelogenous leukemia
  • the cancer is lymphoma, gastric cancer, multiple myeloma, myelodysplastic syndromes, or combinations thereof.
  • the cancer is T-cell leukemia, e.g., adult T-cell leukemia associated with epigenetic methylation of KLF4 gene.
  • the cancer is pediatric B-cell ALL associated with elevated miR A-2902.
  • the cancer is AML, ALL or MDS, e.g., high risk MDS, all of which associated with higher than normal CDX2 activity.
  • the cancer is Hodgkins, Burkitts, or B-cell lymphomas, all of which associated with methylation of KLF4 gene.
  • AML Acute myeloid leukemia
  • ANLL acute nonlymphocytic leukemia
  • AML Acute myeloid leukemia
  • ANLL acute nonlymphocytic leukemia
  • the symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection.
  • risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear.
  • AML As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.
  • risk factors for developing AML include, but are not limited to, preleukemic blood disorders, such as myelodysplasia syndrome or myeloproliferative disease; exposure to anticancer chemotherapy; radiation, such as high amounts of ionizing radiation exposure; and genetic reasons, such as those described in Taylor et al. ("The hereditary basis of human leukemia". In Henderson ES, Lister TA, Greaves MF. Leukemia (6th ed.). Philadelphia: WB Saunders, p. 210. ISBN 0-7216-5381-2), Horwitz et al. ("Anticipation in familial leukemia". Am. J. Hum.
  • AML with multilineage This category includes patients who have had a prior M9895/3
  • MDS myelodysplastic syndrome
  • MPD cardiovascular disease
  • AML occurs most often in elderly patients and often has a
  • AML and MDS This category includes patients who have had prior M9920/3
  • AML or MDS AML or MDS. These leukemias may be characterized by
  • the French-American-British (FAB) classification system divides AML into eight subtypes, M0 through to M7, based on the type of cell from which the leukemia developed and its degree of maturity. Although the WHO classification (see above) may be more useful, the FAB system is still widely used.
  • Acute lymphocytic leukemia also known as acute lymphoblastic leukemia, is an acute leukemia that is characterized by dysregulated proliferation and accumulation of leukemic lymphocytes/lymphoblasts (immature white blood cells such as early B- and T-lymphocyte progenitors) in the bone marrow and various extramedullary sites. ALL is the most common type of cancer in children, and it is a relatively uncommon cancer in adults. Risk factors for developing ALL include, but are not limited to, genetic disorders/mutations and various epigenetic modifications such as those described by Iacobucci et al.
  • Chronic myelogenous leukemia also known as chronic myeloid leukemia, is a chronic leukemia that is characterized by dysregulated/increased proliferation of various blood cells, predominantly myeloid cells in peripheral blood, and their precursors in the bone marrow, resulting in their accumulation in the blood. It is less frequent than chronic lymphocytic leukemia (CLL) in adults in the Western world, and the median age of CML onset is 50-60 years. Risk factors for developing CML also include, but are not limited to, genetic disorders/mutations and various epigenetic modifications such as those described by Florean et al. The disease course is triphasic, starting with an early phase, also known as chronic phase (CP) disease. Then, leukemia stem cells can acquire additional genetic defects.
  • CML chronic myelogenous leukemia
  • ATLL adult T-cell leukaemia
  • HTLV-1 retrovirus human T- lymphotrophic virus type 1
  • Qayyum et al. Abult T-cell leukemia/lymphoma.
  • Arch Pathol Lab Med. 2014 Feb;138(2):282-6 Presently, about 20 million people worldwide are HTLV-1 carriers, with most infected individuals residing in endemic areas such as southern Japan, Africa, the Caribbean basin, and Latin America.
  • the lifelong viral carrier state and long latency (20 ⁇ -0 years) are common after HTLV-1 infection, therefore this type of leukemia/lymphoma is almost exclusively found in adults and is extremely rare in children.
  • the lifetime risk of progression to ATLL in an HTLV- 1 -positive patient is 2.1 % for women and 6.6% for men.
  • the mean age of onset is 60 years old (range, 20-80 years old).
  • the overwhelming majority of ATLL cases occur in patients infected during the early years of life, presumably because of a less efficient immune response in this age group.
  • the prolonged infection may increase chances of accruing subsequent mutations, and ultimately malignant transformation.
  • Major paths of viral transmission are breast feeding, blood exposure, and unprotected sex.
  • the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues in 2008 subclassified ATLL into 4 distinct variants according to the Shimoyama classification: acute (60%), lymphomatous (20%), chronic (15%), and smoldering (5%). There are no absolutely necessary features for each variant, and overlap is seen.
  • the acute variant manifests as marked leukocytosis with atypical lymphocytes and eosinophilia. Symptoms include hypercalcemia with or without osteolytic lesions, renal dysfunction and neuropsychiatric disturbances, elevated lactate dehydrogenase level, central nervous ring-enhancing lesions, and secondary respiratory complications.
  • the lymphomatous variant is an aggressive advanced disease resembling acute-onset subtype, and marked lymphadenopathy without leukemia is a prominent feature of this variant.
  • the chronic variant typically presents with skin rash, leukocytosis with absolute lymphocytosis, mild lymphadenopathy, and hypercalcemia.
  • the smoldering variant is asymptomatic and is characterized by normal white blood cell count with less than 5% circulating atypical lymphoid cells and without associated hypercalcemia or organomegaly, although skin and pulmonary involvement often occur. Progression from the smoldering variant to the acute variant can occur.
  • Lymphoma is a type of blood cancer that occurs when B or T lymphocytes, the white blood cells that form a part of the immune system and help protect the body from infection and disease, divide faster than normal cells or live longer than they are supposed to. Typically, lymphoma presents as a solid tumor of lymphoid cells.
  • the current WHO classification published in 2001 and updated in 2008, is the latest classification of lymphoma and is based upon the foundations laid within the "Revised European-American Lymphoma classification" (REAL):
  • Lymphoplasmacytic lymphoma such as Waldenstrom macroglobulinemia
  • Plasma cell neoplasms • Plasma cell neoplasms:
  • Extranodal marginal zone B cell lymphoma also called MALT lymphoma
  • NZL Nodal marginal zone B cell lymphoma
  • HIV Human Immunodeficiency Virus
  • Primary central nervous system lymphoma occurs most often in immunocompromised patients, in particular those with AIDS, but it can occur in the immunocompetent as well. It has a poor prognosis, particularly in those with AIDS. Treatment can consist of corticosteroids, radiotherapy, and chemotherapy, often with methotrexate.
  • translocation overexpressine cvclin PL Moderately aggressive.
  • lymphocytic lymphomas lymphocytes immunoglobulin adults B-cell chronic 3 to 4% of Small resting CD5, surface 50% Occurs in older lymphocytic lymphomas lymphocytes immunoglobulin adults.
  • leukemia/lymphoma in adults mixed with involves lymph variable number nodes, bone marrow of large activated and spleen. Most cells. Lymph patients have nodes are peripheral blood diffusely effaced involvement.
  • lymphoid fungoides Most Usually small CD4 75% Localized or more common lymphoid cells generalized skin cutaneous with convoluted symptoms. Generally lymphoid nuclei that often indolent. In a more malignancy infiltrate the aggressive variant, epidermis, Sezary's disease, there creatine Pautrier is skin erythema and microabscesseses. peripheral blood involvement.
  • Peripheral T-cell Most Variable. Usually CD3 Probably consists of ly in 1) ho ma-Not- common T a mix small to several rare tumor Otherwise-Specifled cell large lymphoid types. It is often lymphoma cells with disseminated and irregular nuclear generally aggressive. contours.
  • Nodular sclerosis Most Reed-Sternberg CD15, CD30 Most common in form of Hodekin common cell variants and young adults. It often lymphoma type of inflammation. arises in the Lymphoma type Relative Histopathology Immunophenotvpe Overall Other comments incidence 5-vear
  • Hodgkin's usually broad mediastinum or lymphoma sclerotic bands cervical lymph nodes.
  • Gastric cancer a.k.a. stomach cancer, which refers to cancer arising from any part of the stomach.
  • Stomach cancer is often either asymptomatic (producing no noticeable symptoms) or it may cause only nonspecific symptoms (symptoms which are not specific to just stomach cancer, but also to other related or unrelated disorders) in its early stages. It can be diagnosed by gastroscopic exam, upper GI series, or computed tomography or CT scanning. It is previously treated by surgery, chemotherapy, and radiation.
  • Colorectal cancer a.k.a. colon cancer, rectal cancer, bowel cancer or colorectal adenocarcinoma, is a cancer from uncontrolled cell growth in the colon or rectum (parts of the large intestine), or in the appendix. Greater than 75-95% of colon cancer occurs in people with little or no genetic risk. Other risk factors include older age, male gender, high intake of fat, alcohol or red meat, obesity, smoking and a lack of physical exercise. Approximately 10% of cases are linked to insufficient activity. The risk for alcohol appears to increase at greater than one drink per day.
  • Colorectal cancer is a disease originating from the epithelial cells lining the colon or rectum of the gastrointestinal tract, most frequently as a result of mutations in the Wnt signaling pathway that artificially increase signaling activity.
  • the mutations can be inherited or are acquired, and most probably occur in the intestinal crypt stem cell.
  • Genes in the Wnt signaling pathway that are related to colorectal cancer include, but are not limited to, APC, ⁇ - catenin, AXINl , AXIN2, TCF7L2, or NKDl . Beyond the defects in the Wnt-APC-beta-catenin signaling pathway, other mutations must occur for the cell to become cancerous.
  • the p53 protein produced by the TP53 gene, normally monitors cell division and kills cells if they have Wnt pathway defects. Eventually, a cell line acquires a mutation in the TP53 gene and transforms the tissue from an adenoma into an invasive carcinoma.
  • Other apoptotic proteins commonly deactivated in colorectal cancers are TGF- ⁇ and DCC.
  • Other oncogenes overexpressed in colorectal cancer include, genes encoding the proteins KRAS, RAF, and PI3K, which normally stimulate the cell to divide in response to growth factors, can acquire mutations that result in over-activation of cell proliferation.
  • non-hypermutated samples also contain mutated CTN B1, FAM123B, SOX9, ATM, and ARID 1 A.
  • hypermutated tumors display mutated forms of ACVR2A, TGFBR2, MSH3, MSH6, SLC9A9, TCF7L2, and BRAF.
  • the common theme among these genes, across both tumor types, is their involvement in WNT and TGF- ⁇ signaling pathways, which in turn results in increased activity of MYC, a central player in colorectal cancer.
  • myeloma a.k.a. plasma cell myeloma or ahler's disease is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. It can be symptomatic myeloma, asymptomatic myeloma and MGUS (monoclonal gammopathy of undetermined significance). Myeloma is diagnosed with blood tests (serum protein electrophoresis, serum free kappa/lambda light chain assay), bone marrow examination, urine protein electrophoresis, and X-rays of commonly involved bones.
  • MDS Myelodvsplastic syndromes
  • MDS Myelodysplastic syndrome
  • myelodysplastic syndrome refers to a diverse group of hematopoietic stem cell disorders, which are hematological (blood-related) medical conditions with ineffective production (or dysplasia) of the myeloid class of blood cells.
  • MDS is characterized by a cellular marrow with impaired morphology and maturation (dysmyelopoiesis), peripheral blood cytopenias, and a variable risk of progression to acute leukemia, resulting from ineffective blood cell production.
  • the initial hematopoietic stem cell injury can be from causes such as, but not limited to, cytotoxic chemotherapy, radiation, virus, chemical exposure, and genetic predisposition.
  • a clonal mutation predominates over bone marrow, suppressing healthy stem cells.
  • the main cause of cytopenias is increased programmed cell death (apoptosis). As the disease progresses and converts into leukemia, gene mutation rarely occurs and a proliferation of leukemic cells overwhelms the healthy marrow.
  • the disease course differs, with some cases behaving as an indolent disease and others behaving aggressively with a very short clinical course that converts into an acute form of leukemia.
  • Patients with MDS can develop severe anemia and require blood transfusions.
  • the disease worsens and the patient develops cytopenias (low blood counts) caused by progressive bone marrow failure.
  • cytopenias low blood counts
  • Refractory anemia Refractory cytopenia with unilineage dysplasia
  • Refractory anemia with Refractory anemia with ring sideroblasts RARS
  • RARS Refractory anemia with ring sideroblasts - thrombocytosis
  • RARS-t provisional entity
  • JAK2 mutation janus kinase
  • Refractory cytopenia with multilineage dysplasia includes the subset Refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS).
  • RCMD includes patients with pathological changes not restricted to red cells (i.e., prominent white cell precursor and platelet precursor (megakaryocyte) dysplasia.
  • RAEB Refractory anemia with Refractory anemia with excess blasts I and II.
  • RAEB was divided into *RAEB-I (5-9% excess blasts (RAEB) blasts) and RAEB-II (10-19%) blasts, which has a poorer prognosis than RAEB-I.
  • Auer rods may be seen in RAEB-II which may be difficult to distinguish from acute myeloid leukemia.
  • Refractory anemia with The category of RAEB-T was eliminated; such patients are now considered to have excess blasts in acute leukemia.
  • 5q- syndrome typically seen in older women with normal or high transformation (RAEB- platelet counts and isolated deletions of the long arm of chromosome 5 in bone marrow T) cells, was added to the classification.
  • CMML chronic myelomonocytic myelodysplastic syndromes and put in a new category of leukemia (CMML) myelodysplastic-myeloproliferative overlap syndromes.
  • Myelodysplasia unclassifiable (seen in those cases of megakaryocyte dysplasia with fibrosis and others)
  • Signs and symptoms of MDS include, but are not limited to, anemia (low red blood cell count or reduced hemoglobin), with chronic tiredness, shortness of breath, chilled sensation, sometimes chest pain; weakness or feeling tired, paler skin, easy bruising or bleeding, petechiae, fever, neutropenia (low neutrophil count), with increased susceptibility to infection; thrombocytopenia (low platelet count), with increased susceptibility to bleeding and ecchymosis (bruising), as well as subcutaneous hemorrhaging resulting in purpura or petechia; splenomegaly or rarely hepatomegaly; abnormal granules in cells, abnormal nuclear shape and size; and/or chromosomal abnormalities, including chromosomal translocations and abnormal chromosome number.
  • MDS multiple factors can increase risk of MDS, which include, but are not limited to, being male or white, being older than 60 years, past treatment with chemotherapy or radiation therapy, being exposed to certain chemicals, including tobacco smoke, pesticides, and solvents such as benzene, and being exposed to heavy metals, such as mercury or lead.
  • Previous treatment methods for MDS include bone marrow transplantation, use of hematopoietic growth factors or cytokines to stimulate blood cell development in a recipient, such as erythropoietin (EPO), granulocyte macrophage colony stimulating factor (GM-CSF), and granulocyte colony stimulating factor (G-CSF) (Metcalf, 1985, Science 229: 16; Dexter, 1987, J.
  • EPO erythropoietin
  • GM-CSF granulocyte macrophage colony stimulating factor
  • G-CSF granulocyte colony stimulating factor
  • the histology of the cancer is determined before, during or after the treatment.
  • Any suitable test can be used to determine the histology of the cancer.
  • Such test and examination include, but are not limited to, common signs and symptoms of esophaeal cancer, including but not limited to, backwards movement of food through the esophagus and possibly mouth (regurgitation), chest pain not related to eating, difficulty swallowing solids or liquids, heartburn, vomiting blood, hoarseness, chronic cough, hiccups, pneumonia, bone pain, bleeding into the esophagus, and weight loss, medical history and physical exam, imaging tests, chest X-ray, computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, positron emission tomography (PET) scan, bone scan, sputum cytology, needle biopsy, bronchoscopy, endobronchial ultrasound, endoscopic esophageal ultrasound, mediastinoscopy and mediastinotomy, thoracentesis,
  • CT compute
  • CDX2 - KLF4 signaling pathway refers to a group of biological molecules that work together to control one or more cellular functions through CDX2 and/or KLF4, or by affecting the expression or activity of CDX2 or KLF4 as described herein, directly or indirectly. Sometimes the expression level and/or activity of CDX2 and/or KLF4 is also referred to as "CDX2 - KLF4 axis”.
  • CDX2, a.k.a. Caudal Type Homeobox 2, CDX3, Caudal Type HomeoBox Transcription Factor 2, Caudal-Type Homeobox Protein 2, or Homeobox Protein CDX-2 is a member of the caudal-related homeobox transcription factor gene family.
  • the encoded protein is a major regulator of intestine-specific genes involved in cell growth and differentiation. This protein also plays a role in early embryonic development of the intestinal tract. Aberrant expression of this gene is associated with intestinal inflammation and tumorigenesis.
  • Diseases associated with CDX2 include atrophic gastritis, and signet ring cell adenocarcinoma, and among its related super-pathways are Transcription Role of VDR in regulation of genes involved in osteoporosis and Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases.
  • GO annotations related to this gene include transcription regulatory region sequence-specific DNA binding and sequence-specific DNA binding transcription factor activity.
  • An important paralog of this gene is CDX1.
  • CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis (Scholl et al., The Journal of Clinical Investigation, 17(4): 1037-1048), with an mRNA copy numbers varied between about 30 copies to about 89,000 copies.
  • CDX2 gene is turned on” or “CDX2 activity is on” refers to that the mRNA copies of CDX2 in a human subject is at least about 30 copies. Otherwise, the CDX2 gene is considered as being turned off.
  • KLF4 Kriippel-Like Factor 4
  • Gut, EZF, GKLF, Epithelial Zinc Finger Protein EZF, Gut-Enriched Krueppel-Like Factor, Endothelial Kriippel-Like Zinc Finger Protein, or Krueppel-Like Factor 4 is associated with diseases including, but are not limited to, leukemia, skin squamous cell carcinoma, and familial adenomatous polyposis.
  • An important paralog of this gene is KLF1.
  • KLF4 can act both as activator and as repressor. It binds the 5'-CACCC-3' core sequence, such as the promoter region of its own gene. It regulates the expression of key transcription factors during embryonic development, and plays an important role in maintaining embryonic stem cells, and in preventing their differentiation.
  • p21 a.k.a. Cyclin-Dependent Kinase Inhibitor 1A, Cipl , CDJN1, CIPl , WAF1 , CAP20, MDA-6, SDI1, CDK- interacting protein 1 , CDK-interaction protein 1 , cyclin-dependent kinase inhibitor 1 , DNA synthesis inhibitor, Melanoma Differentiation Associated Protein, p21CIP, wild type P53-activated fragment, mDA6, or PCI1, encodes a potent cyclin-dependent kinase inhibitor.
  • the encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at Gl .
  • the expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle Gl phase arrest in response to a variety of stress stimuli.
  • This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair.
  • PCNA proliferating cell nuclear antigen
  • This protein was reported to be specifically cleaved by CASP3-like spases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation.
  • H3K4 demethylase Jaridlb KDM5B, a.k.a. Plu-1 or Rbp2-hl
  • microRNA miR-2909 tumor suppressor p53 (a.k.a TP53 or tumor protein (EC :2.7.1.37))
  • cysteine-aspartic acid protease Caspase-3 Annexin V
  • BCL2 B-cell CLL/Lymphoma 2
  • BCL3 BCL2-associated X protein
  • BAX B-associated X protein
  • BMPs bone morphogenetic proteins
  • Wnt a.k.a.
  • HNF4a hepatocyte nuclear factor 4a
  • Fgf fibroblast growth factors
  • Hox homeobox
  • transcription factor SP1 transcription factor MYC
  • cyclin Dl CCND1 , a.k.a. PRAD1
  • AATF apoptosis-antagonizing transcription factor
  • An active agent of the present invention can modulate the activity of one or more component in the CDX2— KLF4 signaling pathway.
  • the active agent is a small molecule.
  • the active agent is a polypeptide, such as an antibody.
  • the active agent is a polynucleotide, such as siRNA.
  • the active agent modulates the gene copy number of a component in the CDX2 - KLF4 signaling pathway.
  • the active agent modulates the mRNA abundance of a component in the CDX2 - KLF4 signaling pathway.
  • the active agent can increase or decrease the mRNA abundance by 0.5X, l .OX, 1.5X, 2X, 3X, 4X, 5X, 6X, 7X, 8X, 9X, 10X, 100X, 1000X, lOOOOX or more when compared to the mRNA abundance before treatment.
  • the active agent modulates the protein level of a component in the CDX2— LF4 signaling pathway.
  • the active agent can increase or decrease the protein level by 0.5X, l .OX, 1.5X, 2X, 3X, 4X, 5X, 6X, 7X, 8X, 9X, 10X, 100X, 1000X, 10000X or more when compared to the protein level before treatment.
  • the active agent modulates the mRNA and/or protein stability of a component in the CDX2 - KLF4 signaling pathway.
  • the active agent can increase or decrease the stability when compared to the stability before treatment.
  • the active agent modulates the enzymatic activity of a component in the CDX2 - KLF4 signaling pathway. In some embodiments, the active agent can increase or decrease the enzymatic activity when compared to the stability before treatment.
  • the activity of a component in the CDX2 - KLF4 signaling pathway can be determined by any suitable methods known to one skilled in the art. In some embodiments, a biological sample is taken from a subject and analyzed. In some embodiments, the biological sample is then assayed for activity of a component in the CDX2 - KLF4 signaling pathway, such as gene amplification number, RNA, mRNA, cDNA, cRNA, protein, etc.
  • mRNA from a biological sample is directly used in determining the level of activity.
  • the level is determined by hybridization.
  • the RNA is transformed into cDNA (complementary DNA) copy using methods known in the art.
  • the cDNA is labeled with a fluorescent label or other detectable label.
  • the cDNA is then hybridized to a substrate containing a plurality of probes of interest.
  • a probe of interest typically hybridizes under stringent hybridization conditions to at least one DNA sequence of a gene signature.
  • the plurality of probes are capable of hybridizing to the sequences derived from the gene biomarkers under the hybridization conditions.
  • the conditions comprise using 6> ⁇ SSC (0.9 M NaCl, 0.09 M sodium citrate, pH 7.4) at 65° C.
  • the probes may comprise nucleic acids.
  • nucleic acid encompasses known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, peptide-nucleic acids (PNAs).
  • Methods for detecting can include but are not limited to RT-PCR, northern blot analyses, gene expression analyses, microarray analyses, gene expression chip analyses, hybridization techniques (including FISH), expression beadchip arrays, and chromatography as well as any other techniques known in the art.
  • Methods for detecting DNA can include but are not limited to PCR, real-time PCR, digital PCR, hybridization (including FISH), microarray analyses, SNP detection assays, SNP genotyping assays and chromatography as well as any other techniques known in the art.
  • the protein expression level is used in determining the level of activity.
  • the protein expression level of a component in the CDX2 - KLF4 signaling pathway can be determined by any suitable methods known to one skilled in the art. Any suitable methods of protein detection, quantization and comparison can be used, such as those described in Tschesche (Methods in Protein Biochemistry, ISBN Walter de Gruyter, 201 1 , ISBN 31 10252368, 97831 10252361), Goluch et al.
  • the protein expression level of biomarkers are detected and measured by immunohistochemistry (IHC), western blot, protein immunestaining, protein immuneprecipitation, immuneeletrophoresis, immunoblotting, BCA assay, spectrophotometry, mass spectrometry or enzyme assay, or combinations thereof.
  • IHC immunohistochemistry
  • biomarker levels see, e.g., Current Protocols in Molecular Biology, Ed. Ausubel, Frederick M. (2010); Current Protocols in Protein Science Last, Ed. Coligan, John E., et al. (2010); Current Protocols in Nucleic Acid Chemistry, Ed. Egli, Martin (2010); Current Protocols in Bioinformatics, Ed. Baxevanis, Andreas D. (2010); and Molecular Cloning: A Laboratory Manual, Third Edition, Sambrook, Joseph (2001), all of which are incorporated herein by reference in their entirety.
  • antibody of a component in the CDX2 - KLF4 signaling pathway can be used as an active agent.
  • antibody of a component in the CDX2 - KLF4 signaling pathway that negatively control KLF4 and/or p21 , or a component in the CDX2 - KLF4 signaling pathway that are negatively controlled by KLF4 and/or p21 can be used as an active agent.
  • antibodies of CDX2 can be used to treat the cancers of the present invention.
  • antibody of a component in the CDX2 - KLF4 signaling pathway can be used to detect the protein level of the component.
  • a kit for detection is used.
  • Such antibodies and kits are available from EMD Millipore, OriGene Custom Assay Services, R&D Systems for biochemical assays, GenScript Custom Assay Services, Enzo Life Sciences for kits & assays, Cloud-Clone Corp. ELISAs, or Cloud-Clone Corp. CLIAs.
  • the term "antibody” as used herein is intended to include monoclonal antibodies, polyclonal antibodies, and chimeric antibodies. The antibody may be from recombinant sources and/or produced in transgenic animals.
  • antibody fragment as used herein is intended to include Fab, Fab', F(ab')2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, and multimers thereof and biospecific antibody fragments.
  • Antibodies can be fragmented using conventional techniques. For example, F(ab')2 fragments can be generated by treating the antibody with pepsin. The resulting F(ab')2 fragment can be treated to reduce disulfide bridges to produce Fab' fragments. Papain digestion can lead to the formation of Fab fragments.
  • Fab, Fab' and F(ab')2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, biospecific antibody fragments and other fragments can also be synthesized by recombinant techniques.
  • Immunoassays carried out in accordance with the present invention may be homogeneous assays or heterogeneous assays.
  • the immunological reaction usually involves the specific antibody, a labeled analyte, and the sample of interest.
  • the signal arising from the label is modified, directly or indirectly, upon the binding of the antibody to the labeled analyte.
  • Both the immunological reaction and detection of the extent thereof can be carried out in a homogeneous solution.
  • Immunochemical labels which may be employed include free radicals, radioisotopes, fluorescent dyes, enzymes, bacteriophages, or coenzymes.
  • the reagents are usually the sample, the antibody, and means for producing a detectable signal.
  • Samples as described above may be used.
  • the antibody can be immobilized on a support, such as a bead (such as protein A and protein G agarose beads), plate or slide, and contacted with the specimen suspected of containing the antigen in a liquid phase.
  • the support is then separated from the liquid phase and either the support phase or the liquid phase is examined for a detectable signal employing means for producing such signal.
  • the signal is related to the presence of the analyte in the sample.
  • Means for producing a detectable signal include the use of radioactive labels, fluorescent labels, or enzyme labels.
  • an antibody which binds to that site can be conjugated to a detectable group and added to the liquid phase reaction solution before the separation step.
  • the presence of the detectable group on the solid support indicates the presence of the antigen in the test sample.
  • suitable immunoassays include, but are not limited to oligonucleotides, immunoblotting, immunoprecipitation, immunofluorescence methods, chemiluminescence methods, electrochemiluminescence (ECL) or enzyme-linked immunoassays.
  • Antibodies can be conjugated to a solid support suitable for a diagnostic assay (e.g., beads such as protein A or protein G agarose, microspheres, plates, slides or wells formed from materials such as latex or polystyrene) in accordance with known techniques, such as passive binding.
  • Antibodies as described herein may likewise be conjugated to detectable labels or groups such as radiolabels (e.g., 35S, 1251, 1311), enzyme labels (e.g., horseradish peroxidase, alkaline phosphatase), and fluorescent labels (e.g., fluorescein, Alexa, green fluorescent protein, rhodamine) in accordance with known techniques.
  • Antibodies can also be useful for detecting post-translational modifications of proteins, polypeptides, mutations, and polymorphisms, such as tyrosine phosphorylation, threonine phosphorylation, serine phosphorylation, glycosylation (e.g., O-GlcNAc).
  • Such antibodies specifically detect the phosphorylated amino acids in a protein or proteins of interest, and can be used in immunoblotting, immunofluorescence, and ELISA assays described herein. These antibodies are well-known to those skilled in the art, and commercially available.
  • Post- translational modifications can also be determined using metastable ions in reflector matrix- assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) (Wirth, U. et al. (2002) Proteomics 2(10): 1445-51).
  • MALDI-TOF reflector matrix- assisted laser desorption ionization-time of flight mass spectrometry
  • detection reagents can be immobilized on a solid matrix such as a porous strip to form at least one detection site.
  • a solid matrix such as a porous strip
  • polynucleotide or polypeptide arrays or microarrays containing a plurality of detection agents that hybridize to nucleotide or polypeptide of the biomarkers are utilized.
  • the substrate array can be on, e.g., a solid substrate, e.g., a "chip" as described in U.S. Pat. No. 5,744,305.
  • the substrate array can be a solution array.
  • compositions and methods for detecting the components in the CDX2-KLF4 signaling pathway are described in U.S. Patent Nos. 4762706, 5081230, 5300631, 5443956, 7695926, 7785817, 7479376, 7364868 and U.S. Patent Publication Nos. 20050196793, 201 10281277, 20120251509, 20050186642, 2014001 1279, 201 10171221 , 20040235073, 2013001 141 1 , and 20130034862, each of which is incorporated herein by reference in its entirety for all purposes.
  • Anti-cancer compositions that can be utilized in the present invention comprise at least one active agent.
  • the active agent can modulate the activity of the CDX2 - KLF4 signaling pathway.
  • modulate refers to that the compositions can increase, decrease, eliminate, enhance, delay, reduce, or block the activity of a component in the CDX2 - KLF4 signaling pathway.
  • the compounds can decrease the CDX2 activity, and/or increase the KLF4 activity in a human subject.
  • the compounds can increase or decrease the activity of one or more upstream or downstream components in the signaling pathway.
  • the compounds can increase the activity of one or more downstream components that are positively regulated by KLF4 (e.g., p21), or decrease the activity of one or more downstream components in the signaling pathway that are negatively regulated by KLF4 (e.g., SP1). In some embodiments, the compounds can decrease the activity of one or more downstream components that are positively regulated by CDX2, or increase the activity of one or more downstream components in the signaling pathway that are negatively regulated by CDX2.
  • KLF4 e.g., p21
  • KLF4 e.g., SP1
  • the compounds can decrease the activity of one or more downstream components that are positively regulated by CDX2, or increase the activity of one or more downstream components in the signaling pathway that are negatively regulated by CDX2.
  • the anti-cancer agents of the present invention can act through one or more mechanisms. Such mechanisms include, but are not limited to: (1) inhibition of CDX2 activity; (2) induction of KLF4 activity; (3) induction of p21 CDK inhibitor; (4) induction of Gl/S Cell cycle arrest; (5) induction of Caspase 3 enzyme; and (6) induction of apoptosis.
  • the active agents can be chemical compounds or compositions, biological molecules, or combinations thereof. In some embodiments, the active agents are small molecules.
  • the term "small molecule” refers to a molecule having a molecular weight of less than 500 MW, wherein the drug is a non-peptidyl or peptide agent.
  • the active agents are antibodies.
  • the active agents are antibodies.
  • the active agents are polynucleotides, such as siRNA.
  • the active agents contain one or more entities that can inhibit or decrease the activity of CDX2, e.g., at DNA, RNA, protein level, or combinations thereof.
  • the active agents contain one or more antibodies that can reduce, inhibit or delay the activity of a component in the CDX2 - KLF4 signaling pathway that negatively regulates KLF4, or negatively regulated by KLF4.
  • the component can be CDX2, p53, p21 , Caspase-3, Annexin V, BAX, BCL2, BCL3, BMP, Wnt, HNF4a, Fgf, Hox, SPl , MYC, CCNDl , or AATF.
  • the active agents are antibodies.
  • the active agents are siRNA.
  • the anti-CDX2 agent is an anti-CDX2 antibody.
  • an anti-CDX2 antibody at least comprises one or more anti-CDX2 CDRs.
  • antisense RNA, ribozyme, dsRNAi, RNA interference (RNAi) technologies can be used in the present invention to target RNA transcripts of one or more component in the CDX2 - KLF4 signaling pathway.
  • Antisense RNA technology involves expressing in, or introducing into, a cell an RNA molecule (or RNA derivative) that is complementary to, or antisense to, sequences found in a particular mRNA in a cell. By associating with the mRNA, the antisense RNA can inhibit translation of the encoded gene product.
  • the anti-CDX2 agents can be small interference RNA molecules, such as those disclosed by Wang et al. ("siRNA targeting of Cdx2 inhibits growth of human gastric cancer MGC-803 cells", World J Gastroenterol. Apr 28, 2012; 18(16): 1903-1914.)
  • RNA interference is the process of sequence-specific, post-transcriptional gene silencing or transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene.
  • dsRNA double-stranded RNA
  • the RNAi technique is discussed, for example, in Elibashir, et al, Methods Enzymol. 26: 199 (2002); McManus & Sharp, Nature Rev. Genetics 3:737 (2002); PCT application WO 01/75164; Martinez et al, Cell 110:563 (2002); Elbashir et al., supra; Lagos-Quintana et al., Curr. Biol.
  • dsRNA or "dsRNA molecule” or “double-strand RNA effector molecule” refers to an at least partially double-strand ribonucleic acid molecule containing a region of at least about 19 or more nucleotides that are in a double-strand conformation.
  • the double- stranded RNA effector molecule may be a duplex double-stranded RNA formed from two separate RNA strands or it may be a single RNA strand with regions of self-complementarity capable of assuming an at least partially double-stranded hairpin conformation (i.e., a hairpin dsRNA or stem-loop dsRNA).
  • the dsRNA consists entirely of ribonucleotides or consists of a mixture of ribonucleotides and deoxynucleotides, such as RNA DNA hybrids.
  • the dsRNA may be a single molecule with regions of self-complementarity such that nucleotides in one segment of the molecule base pair with nucleotides in another segment of the molecule.
  • the regions of self-complementarity are linked by a region of at least about 3-4 nucleotides, or about 5, 6, 7, 9 to 15 nucleotides or more, which lacks complementarity to another part of the molecule and thus remains single-stranded (i.e., the "loop region").
  • Such a molecule will assume a partially double-stranded stem-loop structure, optionally, with short single stranded 5' and/or 3' ends.
  • the regions of self- complementarity of the hairpin dsRNA or the double-stranded region of a duplex dsRNA will comprise an Effector Sequence and an Effector Complement (e.g., linked by a single-stranded loop region in a hairpin dsRNA).
  • the Effector Sequence or Effector Strand is that strand of the double-stranded region or duplex which is incorporated in or associates with RISC.
  • the double- stranded RNA effector molecule will comprise an at least 19 contiguous nucleotide effector sequence, preferably 19 to 29, 19 to 27, or 19 to 21 nucleotides, which is a reverse complement to the RNA of a target gene, or an opposite strand replication intermediate, or the anti-genomic plus strand or non-mRNA plus strand sequences of the target gene.
  • the dsRNA effector molecule of the invention is a "hairpin dsRNA", a “dsRNA hairpin”, “short-hairpin RNA” or “shRNA”, i.e., an RNA molecule of less than approximately 400 to 500 nucleotides (nt), or less than 100 to 200 nt, in which at least one stretch of at least 15 to 100 nucleotides (e.g., 17 to 50 nt, 19 to 29 nt) is based paired with a complementary sequence located on the same RNA molecule (single RNA strand), and where said sequence and complementary sequence are separated by an unpaired region of at least about 4 to 7 nucleotides (or about 9 to about 15 nt, about 15 to about 100 nt, about 100 to about 1000 nt) which forms a single-stranded loop above the stem structure created by the two regions of base complementarity.
  • the shRNA molecules comprise at least one stem-loop structure comprising a double-stranded stem region of about 17 to about 100 bp; about 17 to about 50 bp; about 40 to about 100 bp; about 18 to about 40 bp; or from about 19 to about 29 bp; homologous and complementary to a target sequence to be inhibited; and an unpaired loop region of at least about 4 to 7 nucleotides, or about 9 to about 15 nucleotides, about 15 to about 100 nt, about 100 to about 1000 nt, which forms a single-stranded loop above the stem structure created by the two regions of base complementarity.
  • the active agents contain one or more entities that can increase the activity of KLF4, or increase the activity of an entity in the CDX2 - KLF4 signaling pathway that is positively regulated by KLF4, or increase the activity of an entity that can positively regulate KLF4, e.g., at DNA, RNA, protein level, or combinations thereof.
  • the active agent of the present invention is a 2-indolyl imidazo[4,5- d]phenanthroline derivative, such as those described in U.S. Patent No. 8,148,392 or U.S. Patent Publication No. 2007/0123553A1 , each of which is herein incorporated by reference in its entirety for all purposes.
  • the compound has the structure of formula I, or a salt thereof:
  • Rl is C1 -C4 alkyl; and R2 is halogen.
  • R 1 is methyl, isopropyl, or t-butyl.
  • the compound has the structure of formula II, or a salt thereof:
  • the compound has the structural formula (III), or a salt thereof:
  • Rl, R2, R3, R4, R6 and R7 are independently selected from hydrogen, halogen, hydroxy 1, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, substituted heterocycle, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, nitro, or cyano or — S(0)1 -2R wherein R is alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, or substituted heteroaryl; and wherein R5 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl; and
  • Rl , R2, R3, R4 are independently hydrogen; halogen; C1 -C4 alkyl; C1 -C4 alkoxy; or C6-C14 aryl;
  • R5 is hydrogen; C1-C4 alkyl; C1-C4 alkyl substituted with C6-C14 aryl; or C4-C6 cycloalkyl;
  • R6 is hydrogen; halogen; C1 -C4 alkyl; C1-C4 alkyl substituted with C5-C6 heterocycloalkyl wherein the heteroatom is N; C6-C14 aryl; C6-C14 aryl substituted with C1-C4 alkyl or halo; C5-C6 cycloalkyl; C5-C6 heterocycloalkyl; or polycycloalkyl.
  • Rl , R2, R3, R4 are independently hydrogen; halogen; C1 -C4 alkyl; C1-C4 alkoxy; or phenyl;
  • R5 is hydrogen; C1 -C4 alkyl; C1-C4 alkyl substituted with phenyl; or cyclopentyl;
  • R6 is hydrogen; halogen; C1 -C4 alkyl; C1-C4 alkyl substituted with C5-C6 heterocycloalkyl wherein the heteroatom is N; phenyl; phenyl substituted with C1-C4 alkyl or halo; C5-C6 cycloalkyl; C5-C6 heterocycloalkyl; or adamantane; and
  • R7 is
  • said compound has a formula selected from the group consisting of:
  • the active agents of the present invention are typically formulated prior to administration.
  • the present invention thus provides pharmaceutical compositions comprising one or more active agents of the present invention.
  • the pharmaceutical compositions comprise a pharmaceutically acceptable carrier, diluent, or excipient.
  • the pharmaceutical compositions are prepared by known procedures using well-known and readily available ingredients.
  • Active agents of the present invention or pharmaceutical compositions comprising the active agents may be administered via any suitable methods, including but not limited to, orally, topically, parenterally, by inhalation or spray, or rectally in dosage unit formulations.
  • the pharmaceutical composition is administered parenterally, paracancerally, transmucosally, tansdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially and intratumorally.
  • the dosage unit formulations contain conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • the active agent is incorporated into an acceptable vehicle to form a composition for topical administration to the affected area, such as hydrophobic or hydrophilic creams or lotions, or into a form suitable for oral, rectal or parenteral administration, such as syrups, elixirs, tablets, troches, lozenges, hard or soft capsules, pills, suppositories, oily or aqueous suspensions, dispersible powders or granules, emulsions, injectables, or solutions.
  • parenteral as used herein includes, but are not limited to, subcutaneous injections, intradermal, intra- articular, intravenous, intramuscular, intravascular, intrastemal, intrathecal injection or infusion techniques.
  • compositions intended for oral use may be prepared in either solid or fluid unit dosage forms.
  • Fluid unit dosage form can be prepared according to procedures known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • An elixir is prepared by using a hydroalcoholic (e.g., ethanol) vehicle with suitable sweeteners such as sugar and saccharin, together with an aromatic flavoring agent.
  • Suspensions can be prepared with an aqueous vehicle with the aid of a suspending agent such as acacia, tragacanth, methylcellulose and the like.
  • Solid formulations such as tablets contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate: granulating and disintegrating agents for example, corn starch, or alginic acid: binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc and other conventional ingredients such as dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose, methylcellulose, and functionally similar materials.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • Soft gelatin capsules are prepared by machine encapsulation of a slurry of the compound with an acceptable vegetable oil, light liquid petrolatum or other inert oil.
  • Aqueous suspensions contain active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxylmethylcellulose, methyl cellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia: dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxy ethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example hepta-decaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxy ethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbito
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl-p-hydroxy benzoate, one or more colouring agents, one or more flavouring agents or one or more sweetening agents, such as sucrose or saccharin.
  • preservatives for example ethyl, or n-propyl-p-hydroxy benzoate
  • colouring agents for example ethyl, or n-propyl-p-hydroxy benzoate
  • flavouring agents for example sucrose or saccharin.
  • sweetening agents such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above, and flavouring agents may be added to provide palatable oral preparations.
  • These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent exemplified by those already mentioned above.
  • Additional excipients for example sweetening, flavouring and colouring agents, may also be present.
  • compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oil phase may be a vegetable oil, for example olive oil or peanut oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or a suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Adjuvants such as local anaesthetics, preservatives and buffering agents can also be included in the injectable solution or suspension.
  • the delivery systems suitable include time-release, delayed release, sustained release, or controlled release delivery systems.
  • a composition of the present invention can be delivered in a controlled release system, such as sustained-release matrices.
  • sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) as described by Langer et al., 1981 , J. Biomed. Mater. Res., 15: 167-277 and Langer, 1982, Chem. Tech., 12:98-105), or poly(vinylalcohol)], polylactides (U.S. Pat. No.
  • the composition may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration.
  • a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al, Surgery 88:507 (1980); Saudek et al, N. Engl. J. Med. 321 :574 (1989).
  • polymeric materials can be used.
  • a controlled release system can be placed in proximity to the therapeutic target, for example liver, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp.1 15-138 (1984). Other controlled release systems are discussed in the review by Langer (Science 249: 1527-1533 (1990).
  • the release of the composition occurs in bursts.
  • systems in which release occurs in bursts includes, e.g., systems in which the composition is entrapped in liposomes which are encapsulated in a polymer matrix, the liposomes being sensitive to specific stimuli, e.g., temperature, pH, light or a degrading enzyme and systems in which the composition is encapsulated by an ionically-coated microcapsule with a microcapsule core degrading enzyme.
  • the release of the composition is gradual/continuous.
  • compositions administered according to the invention incorporate particulate forms, protective coatings, protease inhibitors or permeation enhancers for various routes of administration, such as parenteral, pulmonary, nasal and oral.
  • compositions of the present invention may be administered, together or separately, in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter and polyethylene glycols.
  • compositions and methods of preparing pharmaceutical compositions are known in the art and are described, for example, in “Remington: The Science and Practice of Pharmacy” (formerly “Remingtons Pharmaceutical Sciences”); Gennaro, A., Lippincott, Williams & Wilkins, Philidelphia, Pa. (2000).
  • compositions of the present invention may be administered to a subject by a variety of routes depending on the cancer to be treated, for example, the compositions may be administered orally, topically, parenterally, by inhalation or spray, or rectally in dosage unit formulations.
  • the compounds are administered systemically to a subject, for example, by bolus injection or infusion into a subject's bloodstream or by oral administration.
  • the compounds can be administered prior to, or after, administration of the chemotherapeutic agents, or they can be administered concomitantly.
  • the one or more chemotherapeutic may also be administered systemically, for example, by bolus injection, infusion, or oral administration.
  • compositions of the present invention may be used as part of a neo- adjuvant therapy (to primary therapy), or as part of an adjuvant therapy regimen.
  • the present invention contemplates the use of the pharmaceutical compositions of the present invention at various stages in tumor development and progression, including, but not limited to, in the treatment of advanced and/or aggressive neoplasias (i.e. overt disease in a subject that is not amenable to cure by local modalities of treatment, such as surgery or radiotherapy), metastatic disease, locally advanced disease and/or refractory tumors (i.e. a cancer or tumor that has not responded to treatment).
  • advanced and/or aggressive neoplasias i.e. overt disease in a subject that is not amenable to cure by local modalities of treatment, such as surgery or radiotherapy
  • metastatic disease i.e. a cancer or tumor that has not responded to treatment.
  • primary therapy refers to a first line of treatment upon the initial diagnosis of cancer in a subject.
  • exemplary primary therapies may involve surgery, a wide range of chemotherapies and radiotherapy.
  • adjuvant therapy refers to a therapy that follows a primary therapy and that is administered to subjects at risk of relapsing. Adjuvant systemic therapy is usually begun soon after primary therapy to delay recurrence, prolong survival or cure a subject.
  • compositions of the present invention can be used alone or in combination with one or more other anti-cancer agents, such as chemotherapeutic agents as part of a primary therapy or an adjuvant therapy.
  • Combinations of the pharmaceutical compositions of the present invention and standard chemotherapeutics may act to improve the efficacy of the chemotherapeutic and, therefore, can be used to improve standard cancer therapies.
  • This application can be important in the treatment of drug-resistant cancers which are not responsive to standard treatment.
  • Drug-resistant cancers can arise, for example, from heterogeneity of tumor cell populations, alterations in response to chemotherapy and increased malignant potential. Such changes are often more pronounced at advanced stages of disease.
  • compositions of the present invention can be used alone or in combination with radiation therapeutic.
  • the radiation therapeutic is administered at a dosage of about 40 Gy to about 80 Gy.
  • the dosage is about 50 Gy to about 70 Gy, in some embodiments, the dosage is about 50 Gy to about 65 Gy.
  • the radiation therapy is administered at a dosage of about 50 Gy, about 55 Gy, about 60 Gy or about 65 Gy.
  • the active agents are compounds having the structure of formulas described herein.
  • the actual amount of the compound(s) to be administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
  • the above dosage range is given by way of example only and is not intended to limit the scope of the invention in any way. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing harmful side effects, for example, by first dividing the larger dose into several smaller doses for administration throughout the day.
  • Dosages for a particular individual can be determined by one of ordinary skill in the art using conventional considerations, (e.g. by means of an appropriate, conventional pharmacological protocol).
  • a physician may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained.
  • the dose administered to an individual is sufficient to effect a beneficial therapeutic response in the individual over time, or, e.g., to reduce symptoms, or other appropriate activity, depending on the application.
  • the dose is determined by the efficacy of the particular formulation, and the activity, stability or serum half-life of the composition and the condition of the individual, as well as the body weight or surface area of the individual to be treated.
  • the size of the dose is also determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular vector, formulation, or the like in a particular individual.
  • dosage unit for a compound of the present invention can be about 0.001 mg, about 0.002 mg, about 0.003 mg, about 0.004 mg, about 0.005 mg, about 0.006 mg, about 0.007 mg, about 0.008 mg, about 0.009 mg, about 0.01 mg, about 0.02 mg, about 0.03 mg, about 0.04 mg, about 0.05 mg, about 0.06 mg, about 0.07 mg, about 0.08 mg, about 0.09 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.
  • daily dosages of the compounds of the present invention will typically be about 0.001 mg/kg of body weight, about 0.002 mg/kg of body weight, about 0.003 mg/kg of body weight, about 0.004 mg/kg of body weight, about 0.005 mg/kg of body weight, about 0.006 mg/kg of body weight, about 0.007 mg/kg of body weight, about 0.008 mg/kg of body weight, about 0.009 mg/kg of body weight, about 0.01 mg/kg of body weight, about 0.02 mg/kg of body weight, about 0.03 mg/kg of body weight, about 0.04 mg/kg of body weight, about 0.05 mg/kg of body weight, about 0.06 mg/kg of body weight, about 0.07 mg/kg of body weight, about 0.08 mg/kg of body weight, about 0.09 mg/kg of body weight, about 0.1 mg/kg of body weight, about 0.2 mg/kg of body weight, about 0.3 mg/kg of body weight, about 0.4 mg/kg of body weight, about 0.
  • the dosage form of the present invention is effective to provide a maximum total plasma concentration in said human subject of no more than about 1 pg/mL, about 5 pg/mL, about 10 pg/mL, about 50 pg/mL, about 100 pg/mL, about 500 pg/mL, about 1 ng/mL, about 5 ng/mL, about 10 ng/mL, about 50 ng/mL, about 100 ng/mL, about 500 ng/mL, about 1 ⁇ g/mL, about 5 ⁇ g/mL, about 10 ⁇ g/mL, about 50 ⁇ g/mL, about 100 ⁇ g/mL, about 500 ⁇ g/mL, about 1 mg/mL or more of free base equivalent of the compound.
  • the dosage form is an oral dosage form.
  • the dosage form is an intravenous dosage form.
  • the dosage form is suitable for administration to a human subject particularly for use in the treatment of any of the disorders described herein.
  • the dosage form is a subcutaneous dosage form.
  • Pharmaceutical compositions comprising one or more compounds described herein in combination with one or more other anti-cancer agents can also be used. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
  • the anti-cancer agents are chemotherapeutics.
  • the chemotherapeutics are selected from alkylating agents, anti-metabolites, anti- microtubule agents, Topoisomerase inhibitors, and Cytotoxic antibiotics.
  • chemotherapeutic agents include, but are not limited to, paclitaxel (Taxol®), docetaxel (Taxotere®), cisplatin, carboplatin (Paraplatin®), gemcitabine hydrochloride (Gemzar®), doxorubicin, etoposide (Etopophos®, Vepesid®), pemetrexed (Alimta®), topotecan (Hycamtin®), vinblastine (Velbe®), Vindesine (Eldisine®), vinorelbine (Navelbine®), ifosfamide (Mitoxana®), Mitomycin, and gemcitabine.
  • agents may be given in combination, for example, vinorelbine and cisplatin or carboplatin; gemcitabine with cisplatin or carboplatin or paclitaxel; MIC (mitomycin, ifosfamide and cisplatin); MVP (mitomycin, vinblastine and cisplatin); and EC (etoposide and carboplatin).
  • chemotherapeutic drugs include, but are not limited to, hydroxyurea, busulphan, cisp latin, carboplatin, chlorambucil, melphalan, cyclophosphamide, Ifosphamide, danorubicin, doxorubicin, epirubicin, mitoxantrone, vincristine, vinblastine, Navelbine® (vinorelbine), etoposide, teniposide, paclitaxel, docetaxel, gemcitabine, cytosine, arabinoside, bleomycin, neocarcinostatin, suramin, taxol, mitomycin C and the like.
  • alkylating agents refers to agents that have the ability to alhylate molecules in a subject, including proteins, RNA and DNA.
  • alkylating agents include nitrogen mustards, nitrosoureas, tetrazines, aziridines, cisplatins and derivatives, and non-classical alkylating agents.
  • Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan.
  • Nitrosoureas include N- Nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU) and semustine (MeCCNU), fotemustine and streptozotocin.
  • Tetrazines include dacarbazine, mitozolomide and temozolomide.
  • Aziridines include thiotepa, mytomycin and diaziquone (AZQ).
  • Cisp latin and derivatives include cisplatin, carboplatin and oxaliplatin. They impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules.
  • Non-classical alkylating agents include procarbazine and hexamethylmelamine .
  • anti-metabolites refers to molecule that impedes DNA, RNA, or protein synthesis.
  • anti-metabolites resemble either nucleobases or nucleosides (a nucleotide without the phosphate group), but have altered chemical groups.
  • These drugs exert their effect by either blocking the enzymes required for DNA synthesis or becoming incorporated into DNA or RNA. By inhibiting the enzymes involved in DNA synthesis, they prevent mitosis because the DNA cannot duplicate itself. Also, after misincorperation of the molecules into DNA, DNA damage can occur and programmed cell death (apoptosis) is induced.
  • the anti-metabolites are anti-folates, fiuoropyrimidines, deoxynucleoside analogues and thiopurines.
  • the anti-metabolites are selected from methotrexate, pemetrexed, fiuorouracil, capecitabine, cytarabine, gemcitabine, decitabine, Vidaza, fiudarabine, nelarabine, cladribine, clofarabine, pentostatin, thioguanine and mercaptopurine.
  • anti-microtubule agents refers to chemicals that block cell division by preventing microtubule function.
  • Such agents include taxanes (e.g., paclitaxel (discussed in more detail below) and docetaxel) (Schiff et al., Nature 277: 665-667, 1979; Long and Fairchild, Cancer Research 54: 4355-4361, 1994; Ringel and Horwitz, J. Natl. Cancer Inst. 83(4): 288-291 , 1991; Pazdur et al, Cancer Treat. Rev. 19(4): 351- 386, 1993), campothecin, mitoxantrone, eleutherobin (e.g., U.S. Pat. No.
  • STOP145 and STOP220 stable tubule only polypeptide
  • Such compounds can act by either depolymerizing microtubules (e.g., colchicine and vinblastine), or by stabilizing microtubule formation (e.g., paclitaxel).
  • an anti-tumor agent include mitotic inhibitors, for example vinca alkaloid derivatives such as vinblastine vinorelbine, vindescine and vincristine; colchines allochochine, halichondrine, N-benzoyltrimethyl-methyl ether colchicinic acid, dolastatin 10, maystansine, rhizoxine, taxanes such as taxol (paclitaxel), docetaxel (Taxotere), 2'-N-[3- (dimethylamino)propyl]glutaramate (taxol derivative), thiocholchicine, trityl cysteine, teniposide, methotrexate, azathioprine, fluorouricil, cytocine arabinoside, 2'2'- difluorodeoxycytidine (gemcitabine), adriamycin and mitamycin.
  • mitotic inhibitors for example vinca alkaloid derivatives such as vinblastine vinorelbine
  • Alkylating agents for example cis-platin, carboplatin oxiplatin, iproplatin, Ethyl ester of N-acetyl-DL-sarcosyl-L-leucine (Asaley or Asalex), 1 ,4-cyclohexadiene- 1 ,4-dicarbamic acid, 2,5-bis(l-azirdinyl)-3,6-dioxo-, diethyl ester (diaziquone), l ,4-bis(methanesulfonyloxy)butane (bisulfan or leucosulfan) chlorozotocin, clomesone, cyanomorpholinodoxorubicin, cyclodisone, dianhydroglactitol, fluorodopan, hepsulfam, mitomycin C, hycantheonemitomycin C, mitozolamide, l-(2- chloroethyl)-4-(3-ch
  • DNA anti-metabolites for example 5-fluorouracil, cytosine arabinoside, hydroxyurea, 2-[(3hydroxy-2-pyrinodinyl)methylene]-hydrazinecarbothioamide, deoxyfluorouridine, 5-hydroxy-2-formylpyridine thiosemicarbazone, alpha-2'-deoxy-6- thioguanosine, aphidicolin glycinate, 5-azadeoxycytidine, beta-thio guanine deoxyriboside, cyclocytidine, guanazole, inosine glycodialdehyde, macbecin II, pyrazolimidazole, cladribine, pentostatin, thioguanine, mercaptopurine, bleomycin, 2-chlorodeoxyadenosine, inhibitors of thymidylate synthase such as raltitrexed and pemetrexed disodium, clofarabine, flox
  • DNA/RNA antimetabolites for example, L-alanosine, 5-azacytidine, acivicin, aminopterin and derivatives thereof such as N-[2-chloro-5-[[(2,4-diamino-5-methyl-6- quinazolinyl)methyl]amino]benzoyl]-L-aspartic acid, N-[4-[[(2,4-diamino-5-ethyl-6- quinazolinyl)methyl]amino]benzoyl]-L-aspartic acid, N-[2-chloro-4-[[(2, 4- diaminopteridinyl)methyl]amino]benzoyl]-L-aspartic acid, soluble Baker's antifol, dichloroallyl lawsone, brequinar, ftoraf, dihydro-5-azacytidine, methotrexate, N-(phosphonoacetyl)-L-aspartic acid
  • topoisomerase inhibitors refers to agents that can modulcate the activity of topoisomerase I and/or topoisomerase II.
  • the topoisomerase inhibitor of this invention can be a topoisomerase I inhibitor, which can be, in some embodiments, a camptothecin derivative.
  • a camptothecin derivative of this invention can be, but is not limited to Belotecan (CKD602), Camptothecin, 7-Ethyl-lO-Hydroxy-CPT, 10- Hydroxy-CPT, Rubitecan (9-Nitro-CPT), 7-Ethyl-CPT, Topotecan, Irinotecan, Silatecan (DB67) and any combinations thereof.
  • the topoisomerase I inhibitor can be an indenoisoquinoline derivative, which can be but is not limited to NSC706744, NSC725776, NSC724998 and any combinations thereof.
  • the topoisomerase inhibitor is a topoisomerase II inhibitor, which in some embodiments can be an acridine derivative, which can be but is not limited to Amsacrine, in some embodiments the topoisomerase II inhibitor can be a podophyllotoxin derivative, which can be but is not limited to etoposide, and in some embodiments the topoisomerase II inhibitor can be a bisdioxopiperazine derivative, which can be but is not limited to ICRF-193, dexrazoxane (ICRF-187) and any combinations thereof.
  • acridine derivative which can be but is not limited to Amsacrine
  • the topoisomerase II inhibitor can be a podophyllotoxin derivative, which can be but is not limited to etoposide
  • the topoisomerase II inhibitor can be a bisdioxopiperazine derivative, which can be but is not limited to ICRF-193, dexrazoxane (ICRF-187) and any combinations
  • the topoisomerase inhibitor can be Resveratrol (PMID: 20304553; PMID: 15796584)41 , Epigallocatechin gallate (PMID: 18293940; PMID: 1 1594758; PMID: 1 1558576; PMID: 1313232)42,43, Genistein (PMID: 17458941)44, Daidzein (PMID: 17458941)45.
  • RNAi molecules include small interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), antisense nucleic acid molecules, and the like as are well known in the art.
  • siRNAs and shRNAs of this invention are provided in Table 2.
  • a zinc finger nuclease, an antibody and/or a ribozyme can be employed to inhibit topoisomerase activity in the methods of this invention.
  • cytotoxic antibiotics include, but are not limited to, antinomycin, bleomycin, mitomycin, plicamycin and the like.
  • tyrosine kinase inhibitors include, but are not limited to, nilotinib, imatinib, gefitinib, erlotinib, cetuximab, panitumumab, zalutumumab, nimotuzumab, matuzuman and the like.
  • the other anti-cancer agents are monoclonal antibodies, such as alemtuzumab, bevacizumab, cetuximab, gemtuzumab, rituximab, and trastuzumab; photosensitizers, such as aminolevulinic acid, methyl aminolevulinate, porfimer sodium, and verteporfin; and other agents, such as alitretinoin, altretamine, amsacrine, anagrelide, arsenic trioxide, asparaginase, bexarotene, bortezomib, celecoxib, denileukin diftitox, erlotinib, estramustine, gefitinib, hydroxycarbamide, imatinib, pentostatin, masoprocol, mitotane, pegaspargase, and tretinoin.
  • monoclonal antibodies such as alemtuzumab, bevaci
  • the other anti-cancer agents are those can be used to treat leukemia, such as drugs for Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), and Meningeal Leukemia, include but are not limited to, Abitrexate (Methotrexate), Adriamycin PFS (Doxorubicin Hydrochloride), Adriamycin RDF (Doxorubicin Hydrochloride), Arranon ( elarabine), Asparaginase Erwinia chrysanthemi, Cerubidine (Daunorubicin Hydrochloride), Clafen (Cyclophosphamide), Clofarabine, Clofarex (Clofarabine), Clolar (Clofarabine), Cyclophosphamide, Cytarabine, Cytosar-U (Cytarabine), Cytoxan (Acute Lymphoblastic Le
  • additional anti-cancer agents that can be used together with the compounds of the present invention include agents that can inhibit EGFR (epidermal growth factor receptor) responses, such as EGFR antibodies, EGF antibodies, and molecules that are EGFR inhibitors; VEGF (vascular endothelial growth factor) inhibitors; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor.
  • EGFR inhibitors are described in, for example in WO 95/19970, WO 98/14451, WO 98/02434 and U.S. Pat. No. 5,747,498.
  • EGFR-inhibiting agents include, but are not limited to, the monoclonal antibodies C225 and anti-EGFR 22Mab (ImClone Systems Incorporated of New York, N.Y., USA), the compounds ZD- 1839 (AstraZeneca), BIBX-1382 (Boehringer Ingelheim), MDX-447 (Medarex Inc. of Annandale, N.J., USA), and OLX-103 (Merck & Co. of Whitehouse Station, N.J., USA), VRCTC-310 (Ventech Research) and EGF fusion toxin (Seragen Inc. of Hopkinton, Mass.).
  • VEGF inhibitors for example AG-13736 (Pfizer, Inc.), can also be combined or coadministered with the composition.
  • VEGF inhibitors are described in, for example in WO 99/24440, WO 95/21613, WO 99/61422, U.S. Pat. No. 5,834,504, WO 98/50356 (published Nov. 12, 1998), U.S. Pat. No. 5,883,1 13, U.S. Pat. No. 5,886,020, U.S. Pat. No. 5,792,783, U.S. Pat. No.
  • VEGF inhibitors 6,534,524, WO 99/10349, WO 97/32856, WO 97/22596, WO 98/54093, and WO 98/02437, all of which are herein incorporated by reference in their entirety.
  • Other examples of some specific VEGF inhibitors are IM862 (Cytran Inc. of Kirkland, Wash., USA); AvastinTM or bevacizumab, an anti-VEGF monoclonal antibody (Genentech, Inc. of South San Francisco, Calif); and angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colo.) and Chiron (Emeryville, Calif).
  • ErbB2 receptor inhibitors such as GW-282974 (Glaxo Wellcome pic), and the monoclonal antibodies AR-209 (Aronex Pharmaceuticals Inc. of The Woodlands, Tex., USA) and 2B-1 (Chiron), may be administered in combination with the composition.
  • erbB2 inhibitors include those described in WO 98/02434, WO 99/35146, WO 99/35132, WO 98/02437, WO 97/13760, WO 95/19970, U.S. Pat. No. 5,587,458, and U.S. Pat. No. 5,877,305, each of which is herein incorporated by reference in its entirety.
  • a continuous dosing schedule is used for the treatment.
  • a compound of a dosage form comprising the compound of the present invention is administered once per day, twice per day, three times per day, or more times per day, or continuously during a period of a day, or continuously through out a day, on a daily schedule, or every other day, every third day, every forth day, every fifth day, every sixth day, or every week.
  • the treatment can last a period of time determined by doctors, or until the cancer cells are completely or significantly inhibited.
  • an intermittent dosing schedule is used for the treatment. Such treatment is especially useful if there is toxicity concern.
  • Such treatment is especially useful if there is toxicity concern.
  • Example 1 In Vitro Antiproliferative Activity of LOR-253 in Leukemia, Lymphoma and Multiple Myeloma Cell Lines
  • Antiproliferative activity of LOR-253 was determined by XTT assay as follows. Cells (4 x 10 /well) in 100 ⁇ L of growth medium were seeded in 96-well cell culture plates and incubated overnight at 37°C. The medium was removed and replaced with a total volume of 100 growth medium containing LOR-253 (or 0.1 % DMSO vehicle control), as described in the respective experiments.
  • Suspension cells were plated (4-6 x 10 3 /well) in 50 ⁇ L ⁇ growth medium, and 50 ⁇ L ⁇ growth medium containing LOR-253 (or 0.1% DMSO vehicle control) was added to each well. After incubation of the cells at 37°C for 5 days, cell viability was quantitated with the use of sodium 3'-[l-(phenylamino-carbonyl)-3,4-tetrazolium ⁇ -bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) colorimetric assay (Roche).
  • XTT sodium 3'-[l-(phenylamino-carbonyl)-3,4-tetrazolium ⁇ -bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate
  • XTT labeling reagent (1 mg/rriL) was mixed with electron-coupling reagent, following the manufacturer's instructions, and 50 ⁇ L of the mixture was added directly to the cells. The plates were further incubated at 37°C for 4 h, and the absorbance of each well was measured at 490 nm with a multiwell spectrophotometer (Bio-Tek Instruments Inc.). The data were adjusted relative to the blank and expressed as a percentage of cell growth compared with the vehicle control. (Ref. Huesca et al., Mol Cancer Ther. 2009. 8:2586-96; Lorus publication on LOR- 133)
  • leukemia/lymphoma including AML cell lines, such as HL-60, MV 411 , THP-1 , HEL92.1.7, CCRF-CEM, MOLT-4, Jurkat, K-562, Ramos, and Raji, are the cell lines most sensitive to LOR-253, while other cell lines of lung cancer, bladder cancer, colon cancer, prostate cancer, melanoma, and breast cancer, are less sensitive to LOR-253.
  • AML cell lines such as HL-60, MV 411 , THP-1 , HEL92.1.7, CCRF-CEM, MOLT-4, Jurkat, K-562, Ramos, and Raji
  • AML cell lines such as HL-60, MV 411 , THP-1 , HEL92.1.7, CCRF-CEM, MOLT-4, Jurkat, K-562, Ramos, and Raji
  • the variability in sensitivity to LOR-253 may be attributable to the extent of innate KLF4 suppression.
  • Example 2 KLF4/p21 Induction in AML cell lines in vitro
  • Quantitative RT-PCR was performed in the ABI Prism 7000 Sequence Detection System using cDNAs and human TaqMan Gene Expression Assay primer/probe sets for Kriippel-like factor 4 (KLF4), cyclin-dependent kinase inhibitor 1A (p21) and the ABI TaqMan Universal PCR master mix protocol. Gene expression was normalized with ⁇ -actin gene expression in the same sample, and fold changes in KLF4 or p21 were expressed relative to the corresponding expression level in the DMSO treated samples using the comparative CT method. Treatment of THP1 and HL-60 AML cell lines with LOR-253 results in increased expression KLF4 and p21 (See FIG. 4).
  • Example 3 Treatment with LOR-253 results in Gl/S cell cycle arrest in AML cell lines.
  • THP 1 and HL-60 AML cell lines were treated with DMSO (vehicle control) or 0.5 ⁇ LOR-253 for 16 hours. Cells were washed once in PBS+1% FCS and fixed using ice cold 70% ethanol overnight. Fixed cells were washed twice, resuspended in PI/RNaseA solution, containing 20 ⁇ g/mL propidium iodide and 250 ⁇ g/mL RNaseA, and stained for 30 minuets at 37°C. Stained cells were analyzed using a BD FACSCalibur flow cytometer. The results indicate treatment with LOR-253 results in Gl/S cell cycle arrest in AML cell lines (FIG. 5)
  • Example 4 Treatment with LOR-253 induces apoptosis in cell lines.
  • THP-1 cells were treated with DMSO, 0.5 or 1 uM of LOR-253 for 16 hours. Cells were washed twice with cold PBS and resuspended Annexin V binding buffer. lxlO 5 cells in 100 ⁇ L ⁇ were stained with FITC-Annexin V and propidium iodide, and incubated for 15 minutes at room temperature. After staining, 400 ul of binding buffer was added and the cells were kept on ice until analyzed on a BD FACSCanto flow cytometer. THP-1 cells treated with LOR-253 showed elevated Annexin V staining, indicating induction of apoptosis.
  • THP1 and HL-60 cells were treated with DMSO (vehicle control) or 0.5 ⁇ LOR-253 for 48 hours. Cell lysates were collected using a 1% Triton-X100 lysis. Caspase 3 activity was measured using EnzChek Caspase-3 Assay Kit #1 (Life Technologies) with 5 ⁇ g of cell lysastes according to manufacturer's protocol. Treatment of THP1 and HL-60 cells with LOR-253 results in elevated Caspase 3 activity, indicating induction of apoptosis (FIG. 7).
  • THP1 cells were treated with DMSO (vehicle control) or 0.5 ⁇ LOR-253 for 48 hours.
  • Total RNA was extracted using the TRIzol Plus RNA Purification kit (Ambion, Life Technologies), according to the manufacturer's instructions.
  • First strand cDNA was synthesized from 1 -2 ug total RNA using random hexamer primers (Invitrogen) and the Superscript II Reverse Transcriptase kit (Invitrogen).
  • Quantitative RT-PCR was performed in the ABI Prism 7000 Sequence Detection System using cDNAs and human TaqMan Gene Expression Assay primer/probe sets for BCL2-associated X protein (BAX), B-cell CLL/Lymphoma 2 (BCL2) and the ABI TaqMan Universal PCR master mix protocol. Gene expression was normalized with ⁇ - actin gene expression in the same sample, and fold changes in BAX or BCL2 were expressed relative to the corresponding expression level in the DMSO treated samples using the comparative CT method. Elevation of BAX and repression of BCL2 upon treatment of THP1 cells with LOR-253 indicates induction of apoptosis (FIG. 8).
  • H226 model mice were treated according to several administration schedules as shown in the table below.
  • mice were treated by i.v. bolus injections of LOR-253 HC1 at 1 , 5, and 15 mg/kg. The serum level of LOR-253 was measured. The result indicates that the serum level of LOR-253 has a dose related increase (FIG. 10).
  • mice were treated for 5 consecutive days with 1 , 5, and 15 mg/kg LOR-253. Tumors were measured 16 hours after the last dose, and the KLF-4 protein level was measured.
  • Phase I This was an open-label, phase 1 study to determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.
  • MTD maximum tolerated dose
  • LOR-253 HCl was given in ascending doses until the maximum administered dose or appropriate target dose is reached.
  • LOR-253 HCl was given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient as treated on LOR-253 HCl for 2 cycles for the evaluation.
  • Chemotherapy radiotherapy, biologic therapy, immunotherapy or any other
  • Example 8 In Vitro Antiproliferative Activity of LOR-253 in myelodysplastic syndromes (MPS), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), adult T-cell leukaemia (ATLL), lymphoma, gastric cancer, and multiple myeloma cell lines.
  • MDS myelodysplastic syndromes
  • ALL acute lymphocytic leukemia
  • CML chronic myelogenous leukemia
  • ATLL adult T-cell leukaemia
  • lymphoma gastric cancer
  • multiple myeloma cell lines are determined by XTT assay as described in Example 1.
  • MDS cell lines tested in the assay include, but are not limited to, TER-3 (Mishima et al., New human myelodysplasia cell line, TER-3: G-CSF specific downregulation of Ca2+/calmodulin-dependent protein kinase IV, J Cell Physiol. 2002 May; 191 (2): 183-90), MDS92 (Tohyama et al., A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages, Br J Haematol.
  • ALL cell lines tested in the assay include, but are not limited to, CCRF-CEM (Foley et al., Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965 18:522-529), MOLT-4 (Minowada et al., Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus- derived lymphocytes.
  • CML cell lines tested in the assay include, but are not limited to, K562 (Drexler, Leukemia cell lines: in vitro models for the study of chronic myeloid leukemia. Leuk Res. 1994 Dec; 18(12):919-27).
  • Lymphoma cell lines tested in the assay include, but are not limited to, Ramos, Raji, CA46, Toledo, DB, Mino, and RL.
  • Gastric cancer cell lines tested in the assay include, but are not limited to, AGS (ATCC Accession No. CRL-1739TM), SNU-1 (ATCC Accession No. CRL-5971TM), SNU-5 (ATCC Accession No. CRL-5973TM), SNU-16 (ATCC Accession No. CRL-5974TM), Hs 746T (ATCC Accession No. HTB-135TM), NCI-N87 (N87; ATCC Accession No. CRL-5822TM), KATO III (ATCC Accession No.
  • HTB-103TM SNU-520, SNU-719, NUGC-4, STKM-2, MKN-45, MKN-74, 20M, AKG, ECC4, G42LATE, GCIY, GCIY, GT3TKB, H-l l l , H-162, H-30, H-55, HGC-27, HSC-39, HUG-IN, JRl , KWS, MKN-1 , MKN-28, MKN-7, MKN-74, MKN-74, MKN-74, NCI-N87, NUGC-3, OKAJIMA, SK-GT-1 , SK-GT-2, SK-GT-5, SNU-16, SNU-216, SNU-484, SNU-55, SNU-601, SNU-638, SNU-668, TGBC1 1TKB, TGBC1 1TKB, TMK-1 , and YCC-3
  • Multiple myeloma cell lines tested in the assay include, but are not limited to, HMCLs described in Lombardi et al. (Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer.
  • the in vitro essay results indicate that one or more cell lines of MDS, ALL, CML, ATLL, lymphoma, gastric cancer, or multiple myeloma cell lines are sensitive to LOR-253.
  • First strand cDNA is synthesized from 1 -2 ug total RNA using random hexamer primers (Invitrogen) and the Superscript II Reverse Transcriptase kit (Invitrogen). Quantitative RT-PCR is performed in the ABI Prism 7000 Sequence Detection System using cDNAs and human TaqMan Gene Expression Assay primer/probe sets for Kriippel-like factor 4 (KLF4), cyclin-dependent kinase inhibitor 1A (p21) and the ABI TaqMan Universal PCR master mix protocol.
  • KLF4 Kriippel-like factor 4
  • p21 cyclin-dependent kinase inhibitor 1A
  • Gene expression is normalized with ⁇ -actin gene expression in the same sample, and fold changes in KLF4 or p21 are expressed relative to the corresponding expression level in the DMSO treated samples using the comparative CT method.
  • Example 10 Treatment with LOR-253 results in Gl/S cell cycle arrest in myelodvsplastic syndromes (MDS), ALL, CML, ATLL, lymphoma, gastric cancer, and multiple myeloma cell lines.
  • MDS myelodvsplastic syndromes
  • MDS Myelodysplasia syndromes
  • ALL CML
  • ATLL lymphoma
  • gastric cancer and multiple myeloma cell lines described in Example 8 are treated with DMSO (vehicle control) or 0.1 , 0.2, 0.5 or ⁇ ⁇ LOR-253 for 16 hours.
  • Cells are washed once in PBS+1% FCS and fixed using ice cold 70% ethanol overnight. Fixed cells are washed twice, resuspended in PI/RNaseA solution, containing 20 ⁇ g/mL propidium iodide and 250 ⁇ g/mL RNaseA, and stained for 30 minuets at 37°C.
  • Example 1 1 - Treatment with LOR-253 induces apoptosis in myelodvsplastic syndromes (MDS), ALL. CML. ATLL. lymphoma, gastric cancer, and multiple myeloma cell lines
  • MDS Myelodysplastic syndromes
  • ALL ALL, CML, ATLL, lymphoma, gastric cancer, and multiple myeloma cell lines described in Example 8 are treated with DMSO, 0.1 , 0.2, 0.5 or 1 ⁇ of LOR-253 for 16 hours.
  • Cells are washed twice with cold PBS and resuspended Annexin V binding buffer.
  • lxlO 5 cells in 100 ⁇ L are stained with FITC-Annexin V and propidium iodide, and incubated for 15 minutes at room temperature. After staining, 400 ul of binding buffer is added and the cells are kept on ice until analyzed on a BD FACSCanto flow cytometer.
  • Cell lines are also treated with DMSO (vehicle control) or 0.1, 0.2, 0.5 or 1 ⁇ LOR- 253 for 48 hours.
  • Cell lysates are collected using a 1% Triton-X100 lysis.
  • Caspase 3 activity is measured using EnzChek Caspase-3 Assay Kit #1 (Life Technologies) with 5 ⁇ g of cell lysastes according to manufacturer's protocol.
  • Treatment of one or more cell lines with LOR-253 results in elevated Caspase 3 activity, indicating induction of apoptosis.
  • Total R A of treated cell lines are extracted using the TRIzol Plus RNA Purification kit (Ambion, Life Technologies), according to the manufacturer's instructions.
  • First strand cDNA is synthesized from 1 -2 ⁇ g total RNA using random hexamer primers (Invitrogen) and the Superscript II Reverse Transcriptase kit (Invitrogen).
  • Quantitative RT-PCR is performed in the ABI Prism 7000 Sequence Detection System using cDNAs and human TaqMan Gene Expression Assay primer/probe sets for BCL2-associated X protein (BAX), B-cell CLL/Lymphoma 2 (BCL2) and the ABI TaqMan Universal PCR master mix protocol.
  • BAX BCL2-associated X protein
  • BCL2 B-cell CLL/Lymphoma 2
  • Model mice of myelodysplastic syndromes (MDS), ALL, CML, ATLL, lymphoma, gastric cancer, and multiple myeloma are created according to standard procedures. The model mice are treated according to several administration schedules as shown in the table below.
  • Example 13 in vivo Dose-dependent pharmacokinetic (PK) and pharmacodynamic (PD) responses in Xenograft model mice treated by LOR-253 HCL with myelodvsplastic syndromes (MPS), ALL, CML, ATLL, lymphoma, gastric cancer, and multiple myeloma
  • MPS myelodvsplastic syndromes
  • mice are treated for 5 consecutive days with 1 , 5, and 15 mg/kg LOR-253. Tumors are measured 16 hours after the last dose, and the KLF-4 protein level is measured. This results show that average KLF4 protein levels in one or more treatment increase in a dose-dependent manner, correlating with tumor biodistribution and dose-response antitumor activity.
  • LOR-253 HCl The anti-tumor activity of LOR-253 HCl was evaluated in another in vivo animal model of human AML.
  • the human AML cell line Kasumi-1 was implanted subcutaneously into athymic nude mice. Some tumor-bearing mice were treated with LOR-253 HCl at 30 mg/kg (15 mg/kg twice per day) for two consecutive days per week for four weeks (the "LOR-253 treatment group").
  • LOR-253 was administered by intravenous (i.v.) bolus injection as the hydrochloric salt form (LOR-253-HC1) formulated in 20% Polyethylene Glycol 400, 10% Propylene Glycol, and 10% Solutol HS in 60% water.
  • tumor-bearing mice were treated with a formulation that did not have LOR-253 (the "vehicle control group").
  • Mean tumor volumes +/- standard error (SE) were calculated from each measurement and then plotted in a standard graph to compare the anti-tumor efficacy of drug treatment to that of control (FIG. 15). Toxicity was assessed by clinical observations and by measurement of mouse body weight in grams twice per week over the course of the study. Mean body weights were calculated from each measurement and then plotted to compare body weight changes in the drug treatment group to that of control (FIG. 16).
  • the toxicity results as shown in FIG. 16 demonstrate that the mice in the treatment group did not show body weight loss. The mice in the treatment group also did not show other overt signs of toxicity. These results indicate that this treatment schedule was well tolerated.
  • LOR-253 HC1 showed significant tumor growth inhibition as a single agent at twice per week dosing without obvious signs of toxicity, suggesting that LOR-253 HC1 has a sufficient therapeutic window and that this agent is a potential chemotherapeutic agent for the treatment of AML.
  • Group 1 Negative control group. LOR-253 HCl control vehicle, 2X/day, 3 cycles of 2 consecutive days, 5 days between cycles, i.v., plus 1% D-mannitol every four days by s.c. injection
  • Group 2 Azacitidine (in 1 % D-mannitol) at 10 mg/kg IX on days 1 ,4, 8, 1 1 , 15 and 18 by subcutaneous (s.c.) injection
  • Group 4 LOR-253 HCl at 15 mg/kg 2X/day (bid) for 3 cycles, each cycle is 1 day of
  • n 9 (1T-6B )
  • Group 5 Combination of LOR-253 (2T-5B) and azacitidine.
  • LOR-253 HCl at 15 mg/kg bid for 3 cycles, each cycle is 2 consecutive days of dosing per week with 5 days of non-dosing, i.v., n 9 (2T-5B) plus azacitidine at 10 mg/kg IX every four days by s.c. injection
  • Group 6 Combination of LOR-253 (1T-6B) and azacitidine.
  • LOR-253 HCl at 15 mg/kg bid for 3 cycles, each cycle is 1 day of dosing per week with 6 days of non- dosing, i.v., n 9 (1T-6B) plus azacitidine at 10 mg/kg IX every four days by s.c. injection
  • SE standard error
  • FIG. 17 The tumor inhibition results as shown in FIG. 17 demonstrate that LOR-253 HCl administered alone at 15 mg/kg twice per day for either one (Group 4) or two (Group 3) consecutive days per week inhibited growth of HL-60 tumors to approximately the same extent as or slightly more than azacitidine alone.
  • FIG. 18 and FIG. 19 show the tumor size data from individual animals at the beginning (Day 1) and end (Day 19) of this study.
  • LOR-253 HCl in combination with azacitadine resulted in even higher levels of tumor growth inhibition than either single agent alone, LOR-253 HCl may also provide additive anticancer efficacy to a standard of care chemo therapeutic for hematological malignancies.
  • LOR-253- 15mg/kg-iv,bid,2T/wk- Day 26 [00222] Tumor sizes were measure as described in Examples 14 and 15, and the results are shown in FIG. 20. LOR-253 HC1 showed significant tumor growth inhibition as a single agent in this AML animal model as well.
  • Group 1 Control received i.v. treatments with LOR-253 control vehicle(CV) on Days 1 ,2,8,9,15 &16; received subcutaneous (SC) treatments with Azacitidine control vehicle on Days 1 ,4,8,1 1 ,15,18,22,25,29 &32; and received intraperitoneal (IP) treatments with LOR-253- CV on Days 22,23,24,25, 29&30.
  • LOR-253 control vehicle(CV) on Days 1 ,2,8,9,15 &16
  • SC subcutaneous
  • Azacitidine control vehicle on Days 1 ,4,8,1 1 ,15,18,22,25,29 &32
  • IP intraperitoneal
  • Group-2- LOR-253 received i.v. treatments on Days 1 ,2,8,9,15 &16; received IP treatments on Days 22,23,24,25, 29&30
  • Group-3-Azacitidine received SC treatments on Days 1 ,4,8,11 ,15,18,22,25,29 &32.
  • Group-4-Combination received i.v. treatments with LOR-253 on Days 1,2,8,9,15 &16; received IP treatments with LOR-253 on Days 22,23,24 &25; and received SC- treatment with Azacitidine on Days 1,4,8,1 1 ,15,18,22 &25

Abstract

La présente invention concerne des compositions et des procédés de traitement de cancers. Dans certains modes de réalisation, l'invention concerne l'utilisation d'agents qui peuvent moduler un constituant dans la voie de signalisation CDX2-KLF4 pour traiter des syndromes myélodysplasiques (MDS), une leucémie myélogène aiguë (AML), une leucémie lymphoïde aiguë (ALL), une leucémie de lymphocytes T adultes (ATLL), un lymphome, un cancer de l'estomac, un myélome multiple ou des combinaisons de ces derniers, ou un état associé à une activité anormale de la voie de signalisation CDX2-KLF4.
PCT/US2014/059140 2013-10-04 2014-10-03 Compositions et procédés de traitement de cancers WO2015051302A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP14850583.7A EP3052102B1 (fr) 2013-10-04 2014-10-03 Compositions pour le traitement de cancers
CN201480064470.2A CN105764511B (zh) 2013-10-04 2014-10-03 用于治疗癌症的组合物和方法
DK14850583.7T DK3052102T3 (da) 2013-10-04 2014-10-03 Sammensætninger til behandling af cancere
ES14850583T ES2775579T3 (es) 2013-10-04 2014-10-03 Composiciones para el tratamiento del cáncer
EP19197122.5A EP3650023A1 (fr) 2013-10-04 2014-10-03 Compositions pour le traitement de cancers
KR1020167011859A KR20160058960A (ko) 2013-10-04 2014-10-03 암을 치료하기 위한 조성물과 방법
JP2016519769A JP6946000B2 (ja) 2013-10-04 2014-10-03 がんの治療用組成物及び方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361887285P 2013-10-04 2013-10-04
US61/887,285 2013-10-04
US201361919023P 2013-12-20 2013-12-20
US61/919,023 2013-12-20
US201462017505P 2014-06-26 2014-06-26
US62/017,505 2014-06-26
US201462037868P 2014-08-15 2014-08-15
US62/037,868 2014-08-15

Publications (1)

Publication Number Publication Date
WO2015051302A1 true WO2015051302A1 (fr) 2015-04-09

Family

ID=52777444

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/059142 WO2015051304A1 (fr) 2013-10-04 2014-10-03 Compositions, biomarqueurs et leur utilisation dans le traitement du cancer
PCT/US2014/059140 WO2015051302A1 (fr) 2013-10-04 2014-10-03 Compositions et procédés de traitement de cancers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2014/059142 WO2015051304A1 (fr) 2013-10-04 2014-10-03 Compositions, biomarqueurs et leur utilisation dans le traitement du cancer

Country Status (9)

Country Link
US (4) US9567643B2 (fr)
EP (2) EP3052102B1 (fr)
JP (3) JP6946000B2 (fr)
KR (1) KR20160058960A (fr)
CN (1) CN105764511B (fr)
DK (1) DK3052102T3 (fr)
ES (1) ES2775579T3 (fr)
HK (1) HK1225647A1 (fr)
WO (2) WO2015051304A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10080739B2 (en) 2003-11-14 2018-09-25 Aptose Biosciences Inc. Aryl imidazoles and their use as anti-cancer agents
US11104957B2 (en) 2013-10-04 2021-08-31 Aptose Biosciences, Inc. Compositions and methods for treating cancers
US11149047B2 (en) 2017-10-30 2021-10-19 Aptose Biosciences, Inc. Aryl imidazoles for treatment of cancer

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018074748A2 (pt) * 2016-06-02 2019-03-06 Immunocore Limited composição terapêutica biespecífica de redirecionamento de células t, e método de tratamento de câncer gp100 positivo em um paciente
CN106916788B (zh) * 2017-04-12 2019-06-25 北京市肿瘤防治研究所 人紫杉醇耐药胃癌细胞hgc-27/ptx及其制备方法
KR20220124177A (ko) * 2019-12-06 2022-09-13 유니버시티 헬스 네트워크 급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법
US20210380586A1 (en) * 2020-06-02 2021-12-09 Aptose Biosciences Inc. 2-indolyl imidazo[4,5-d]phenanthroline polymorphs and compositions regarding the same
CN113134077A (zh) * 2021-04-06 2021-07-20 中山大学附属第六医院 一种高效的转录因子klf4在调控结直肠癌转移的应用

Citations (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4230767A (en) 1978-02-08 1980-10-28 Toyo Boseki Kabushiki Kaisha Heat sealable laminated propylene polymer packaging material
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
EP0058481A1 (fr) 1981-02-16 1982-08-25 Zeneca Limited Compositions pharmaceutiques pour la libération continue de la substance active
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
EP0133988A2 (fr) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Préparations pharmaceutiques contenant des peptides régulateurs à libération retardée et procédé pour leur préparation
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
EP0239362A2 (fr) 1986-03-27 1987-09-30 Imperial Chemical Industries Plc Agents anti-tumeureux
US4720459A (en) 1985-02-14 1988-01-19 Medical College Of Wisconsin Research Foundation, Inc. Myelomas for producing human/human hybridomas
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US4762706A (en) 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US5081230A (en) 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US5300631A (en) 1982-10-01 1994-04-05 Massachusetts Institute Of Technology Antibodies specific for either ras photo-oncogene encoded P21 proteins or ras oncogene encoded P21 proteins but not for both and method of producing same
WO1995019970A1 (fr) 1994-01-25 1995-07-27 Warner-Lambert Company Composes tricycliques pouvant inhiber les tyrosines kinases de la famille des recepteurs du facteur de croissance epidermique
WO1995021613A1 (fr) 1994-02-09 1995-08-17 Sugen, Inc. Composes destines au traitement de troubles associes a la vasculogenese et/ou a l'angiogenese
US5443956A (en) 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US5473057A (en) 1994-11-09 1995-12-05 The Regents Of The University Of California Eleutherobin and analogs thereof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1997013760A1 (fr) 1995-10-11 1997-04-17 Glaxo Group Limited Composes condenses tricycliques et compositions pharmaceutiques les contenant
WO1997022596A1 (fr) 1995-12-18 1997-06-26 Zeneca Limited Derives de quinazoline
WO1997032856A1 (fr) 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
WO1998002437A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998002434A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998014451A1 (fr) 1996-10-02 1998-04-09 Novartis Ag Derive de pyrazole condense et procede pour sa preparation
US5744305A (en) 1989-06-07 1998-04-28 Affymetrix, Inc. Arrays of materials attached to a substrate
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5792783A (en) 1995-06-07 1998-08-11 Sugen, Inc. 3-heteroaryl-2-indolinone compounds for the treatment of disease
WO1998050356A1 (fr) 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
WO1998054093A1 (fr) 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
US5877305A (en) 1992-02-06 1999-03-02 Chiron Corporation DNA encoding biosynthetic binding protein for cancer marker
WO1999010349A1 (fr) 1997-08-22 1999-03-04 Zeneca Limited Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
WO1999024440A1 (fr) 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
WO1999035132A1 (fr) 1998-01-12 1999-07-15 Glaxo Group Limited Composes heterocycliques
WO1999035146A1 (fr) 1998-01-12 1999-07-15 Glaxo Group Limited Composes heteroaromatiques bicycliques agissant comme inhibiteurs de la tyrosine kinase
WO1999061422A1 (fr) 1998-05-29 1999-12-02 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
WO2001075164A2 (fr) 2000-03-30 2001-10-11 Whitehead Institute For Biomedical Research Mediateurs d'interference arn specifiques de sequences arn
US6534524B1 (en) 1999-07-02 2003-03-18 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
US20040235073A1 (en) 1999-05-19 2004-11-25 Ruppert J. Michael Kruppel-like transcriptional factor KLF4/GKLF and uses thereof
US20050186642A1 (en) 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
US20050196793A1 (en) 2000-03-27 2005-09-08 Waldman Scott A. Detection of CDX2 expression
WO2006126177A2 (fr) 2005-05-25 2006-11-30 Genesense Technologies Inc. Derives de 2-indolyl imidazo[4,5-d]phenanthroline et utilisation dans le traitement du cancer
US20070123553A1 (en) 2003-11-14 2007-05-31 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
US20090232767A1 (en) * 2006-09-07 2009-09-17 Frankel Arthur E Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
WO2010102393A1 (fr) * 2009-03-12 2010-09-16 Lorus Therapeutics Inc. Dérivés de 2-indolylimidazo[4,5-d]phénanthroline et leur utilisation pour inhiber l'angiogenèse
US20100311683A1 (en) * 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
US20110097343A1 (en) * 2009-10-26 2011-04-28 Djordje Atanackovic Diagnosis and therapy of hematological malignancies
US20110171221A1 (en) 2008-04-10 2011-07-14 University Of Florida Research Foundation Compositions and methods for the treatment of a neoplasia
US20110281277A1 (en) 2010-05-17 2011-11-17 Lee Ah Won Composition, kit, and method for diagnosing colorectal cancer or ovarian cancer
US20110306602A1 (en) * 2007-04-24 2011-12-15 Philipp Wabnitz 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
WO2012006032A2 (fr) * 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Traitement du cancer du sang
US20120100131A1 (en) * 2009-04-10 2012-04-26 Kyushu University, National University Corp. Method for treatment of blood tumor using anti-tim-3 antibody
US20120251509A1 (en) 2009-10-22 2012-10-04 Waldman Scott A Cell-based anti-cancer compositions and methods of making and using the same
US20130011411A1 (en) 2010-01-06 2013-01-10 Pestell Richard G Methods and compositions for the diagnosis, prognosis, and treatment of cancer
US20130034862A1 (en) 2008-07-10 2013-02-07 Nodality, Inc. Methods for Diagnosis, Prognosis and Methods of Treatment
US20130177632A1 (en) * 2002-08-19 2013-07-11 Raed H. Al-Qawasmeh 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
US20130253842A1 (en) * 2011-12-09 2013-09-26 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US20140011279A1 (en) 2008-06-27 2014-01-09 Kyoto University Method of efficiently establishing induced pluripotent stem cells

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE585507A (fr) 1960-03-31
US3297710A (en) 1963-04-09 1967-01-10 Du Pont Oxoarylidene-imidazoles
US3714181A (en) 1970-12-31 1973-01-30 American Cyanamid Co 2-aryl-5,10-diphenylphenanthro(9,10-d)azoles
US4089747A (en) 1976-08-09 1978-05-16 Eastman Kodak Company Compositions for the detection of hydrogen peroxide
DE3141063A1 (de) 1981-10-13 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue imidazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4423046A (en) 1982-04-05 1983-12-27 Sterling Drug Inc. Antibacterial and antiprotozoal 1-methyl-5-nitro-2-(2-phenylvinyl)imidazoles
DE3422175A1 (de) 1984-06-04 1985-12-19 Julius Dr. 8000 München Kern Verfahren zur beimischung von ammoniak zu saure schadstoffe enthaltenden abgasen oder luft
JPS614960A (ja) 1984-06-19 1986-01-10 Fuji Photo Film Co Ltd 分析試薬および多層化学分析要素
US4758421A (en) 1985-03-15 1988-07-19 The Board Of Trustees Of The Leland Stanford Junior University Bleomycin conjugates and method
IT1214597B (it) 1985-04-15 1990-01-18 Rorer Italiana Spa Derivati dell'imidazolo adattivita' antimicotica, procedimento ed intermedi per laloro preparazione e composizioni che li contengono.
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4902705A (en) 1985-12-12 1990-02-20 Ube Industries, Ltd. Imidazole derivatives, an antibacterial and antifungal agent comprising said derivatives, and a process for the production of said imidazole derivatives
US5024935A (en) 1987-12-18 1991-06-18 Eastman Kodak Company Dye-providing composition, diagnostic test kit and their use in method for ligand determination using peroxidase labeled-receptor
US5047318A (en) 1988-06-13 1991-09-10 Eastman Kodak Company Imidazole leuco dye composition containing 4'-hydroxyacetanilide, diagnostic kit and method using same
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US5514550A (en) 1989-02-03 1996-05-07 Johnson & Johnson Clinical Diagnostics, Inc. Nucleic acid test article and its use to detect a predetermined nucleic acid
US5441716A (en) 1989-03-08 1995-08-15 Rocky Research Method and apparatus for achieving high reaction rates
JP2931400B2 (ja) 1989-03-08 1999-08-09 ロッキー・リサーチ 固体ガス反応器システムにおける高反応速度を達成するための方法および装置
JPH02258017A (ja) 1989-03-31 1990-10-18 Babcock Hitachi Kk 固体還元剤を用いた排ガス脱硝装置
US4970226A (en) 1989-10-03 1990-11-13 Harbor Branch Oceanographic Institution, Inc. Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents
US5161389A (en) 1990-11-13 1992-11-10 Rocky Research Appliance for rapid sorption cooling and freezing
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
ZA945363B (en) 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
US5496702A (en) 1994-09-01 1996-03-05 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having stable leuco dye coatings
PT797575E (pt) 1994-12-13 2004-02-27 Hoffmann La Roche Derivados de imidazol utilizaveis como inibidores de proteina quinase em particular da tirosina quinase do egf-r
TW424172B (en) 1995-04-19 2001-03-01 Hitachi Chemical Co Ltd Photosensitive resin composition and photosensitive element using the same
US5700826A (en) 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
US5753687A (en) 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
EP0906099A4 (fr) 1996-04-03 2001-02-07 Merck & Co Inc Methode de traitement du cancer
US5693589A (en) 1996-05-08 1997-12-02 Eastman Kodak Company Thermal imaging recording element
EP0812829A1 (fr) 1996-06-14 1997-12-17 Ontogen Corporation Imidazoles substitués comme modulateurs pour suppression de la résistance à plusieurs médicaments
IT240917Y1 (it) 1996-10-01 2001-04-11 Stefcom Spa Scarpa con tomaia avente porzione per la traspirazione dell'internodella scarpa
EP0946518A1 (fr) 1996-12-16 1999-10-06 Ontogen Corporation Modulateurs de proteines possedant des unites de reconnaissance de la phosphotyrosine
JP2001505585A (ja) 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5809775A (en) 1997-04-02 1998-09-22 Clean Diesel Technologies, Inc. Reducing NOx emissions from an engine by selective catalytic reduction utilizing solid reagents
PT1028954E (pt) 1997-04-24 2003-11-28 Ortho Mcneil Pharm Inc Imidazoles substituidos uteis no tratamento de doencas inflamatorias
JPH10319584A (ja) 1997-05-21 1998-12-04 Brother Ind Ltd マイクロカプセルを用いた感光性記録材料
DE19728343C5 (de) 1997-07-03 2013-02-21 Robert Bosch Gmbh Verfahren und Vorrichtung zur selektiven katalytischen NOx-Reduktion
WO1999001128A1 (fr) 1997-07-03 1999-01-14 Neurogen Corporation Certains derives diarylimidazoles; nouvelle classe de ligands specifiques de neuropeptide y (npy)
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US6329375B1 (en) 1997-08-05 2001-12-11 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
GB9717804D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
JPH11199582A (ja) 1998-01-05 1999-07-27 Sagami Chem Res Center ４（５）−（３−インドリル）イミダゾール誘導体
WO1999047502A1 (fr) 1998-03-18 1999-09-23 Wake Forest University Chelateurs de metaux cytotoxiques, leur procede d'obtention et leurs utilisations
US6288212B1 (en) 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
WO2000033836A1 (fr) 1998-12-04 2000-06-15 Ontogen Corporation Heterocycles a 5 chainons pour le traitement de maladies humaines dans lesquelles interviennent des modulateurs de selectines
JP2000273088A (ja) 1999-01-18 2000-10-03 Nippon Soda Co Ltd トリフェニルイミダゾール化合物および農園芸用殺菌剤
JP2000281588A (ja) 1999-03-30 2000-10-10 Sankyo Co Ltd ガンの予防又は治療薬及びそのスクリーニング方法
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
AU4640600A (en) 1999-05-11 2000-11-21 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
DE19925631A1 (de) 1999-06-04 2000-12-07 Georg Gros Beschichtungsverfahren und Beschichtungsgemisch
WO2000078761A1 (fr) 1999-06-23 2000-12-28 Sepracor, Inc. Antibacteriens indolyl-benzimidazole et procedes d'utilisation
US6266955B1 (en) 1999-08-20 2001-07-31 Caterpillar Inc. Diagnostic system for an emissions control on an engine
CN1088713C (zh) 1999-09-24 2002-08-07 中国科学院化学研究所 用于二级pH传感的钌（Ⅱ）多吡啶配合物及其制备方法
CN1087744C (zh) 1999-09-24 2002-07-17 中国科学院化学研究所 一种钌（ⅱ）多吡啶配合物及其制备方法
DE60041880D1 (de) 1999-10-08 2009-05-07 Taiji Biomedical Inc Verfahren zur verbesserung der chemotherapie
US7115645B2 (en) 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
HUP0301181A2 (en) 2000-09-21 2007-02-28 Smithkline Beecham Plc Imidazole derivatives as raf kinase inhibitors
EP1335726B1 (fr) 2000-10-13 2011-05-25 Nanotherapeutics, Inc. Formes modifiees du promedicament ap
WO2002046168A1 (fr) 2000-12-07 2002-06-13 Astrazeneca Ab Composes therapeutiques de benzimidazole
MXPA03008142A (es) 2001-03-09 2003-12-12 Pfizer Prod Inc Nuevos compuestos antiinflamatorios de bencimidazol.
JP2002275458A (ja) 2001-03-21 2002-09-25 Fukuoka Prefecture フォトクロミックアモルファス材料及び高密度光記録媒体
US7759373B2 (en) 2001-04-16 2010-07-20 Mitsubishi Tanabe Pharma Corporation Large conductance calcium-activated K channel opener
US6916440B2 (en) 2001-05-31 2005-07-12 3M Innovative Properties Company Processes and apparatus for making transversely drawn films with substantially uniaxial character
JP3759882B2 (ja) 2001-06-01 2006-03-29 株式会社日立製作所 ポンプ装置
DE10134775A1 (de) 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
CA2455181C (fr) 2001-08-01 2010-04-06 Merck & Co., Inc. Derives de la benzimidazo[4,5-f]isoquinolinone
RS50939B (sr) 2001-10-19 2010-08-31 Ortho-Mcneil Pharmaceutical Inc. 2-fenil benzimidazoli i imidazo-/4,5/-piridini kao cdsi/chk2 -inhibitori i pomoćna sredstva u hemoterapiji ili terapiji zračenja pri lečenju kancera
CA2473505A1 (fr) 2002-02-07 2003-08-14 Ellen M. Leahy Nouveaux hydroxamates bicycliques servant d'inhibiteurs de histone desacetylase
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
CA2482087C (fr) 2002-06-19 2011-04-19 Kurita Water Industries Ltd. Methode de stockage de l'hydrogene, compose d'inclusion de l'hydrogene et procede pour le produire
EP1532118A2 (fr) 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Composes d'imidazole pour le traitement des infections par le virus de l'hepatite c
DE10251472A1 (de) 2002-11-06 2004-05-19 Robert Bosch Gmbh Verfahren zur Nachbehandlung von Abgasen und Anordnung hierzu
WO2004071464A2 (fr) * 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Applications therapeutiques et diagnostiques de genes s'exprimant de maniere differentielle dans des cellules souches lympho-hematopoietiques
US7989089B2 (en) 2003-04-17 2011-08-02 Lg Display Co., Ltd. Organic luminescent compounds and methods of making and using same
CA2425797C (fr) 2003-04-17 2013-10-15 Xerox Corporation Dispositifs electroluminescents organiques
DE10323591A1 (de) 2003-05-16 2004-12-02 E.G.O. Elektro-Gerätebau GmbH Verfahren und Vorrichtung zur Erzeugung eines Gases aus einem Sublimationsgut
US20050195793A1 (en) 2004-03-05 2005-09-08 Lockheed Martin Corporation System for locally synchronizing a group of mobile devices
US20050282285A1 (en) 2004-06-21 2005-12-22 Eaton Corporation Strategy for controlling NOx emissions and ammonia slip in an SCR system using a nonselective NOx/NH3
EP1778586B1 (fr) 2004-08-03 2017-04-05 Amminex Emissions Technology A/S Matiere de stockage d'ammoniac solide et matiere de distribution associee
EP1868941B9 (fr) 2005-02-03 2017-02-15 Amminex Emissions Technology A/S Stockage a densite elevee d'ammoniac
JP5334575B2 (ja) * 2005-05-25 2013-11-06 ローラス セラピューティクス インコーポレーテッド ２−インドリルイミダゾ［４，５‐ｄ］フェナントロリン派生物および癌治療におけるそれらの使用
JP2008546968A (ja) 2005-06-29 2008-12-25 アムミネクス・アー／エス 固体アンモニア貯蔵媒体からのアンモニアの安全な制御された送出のための方法および装置
KR100694181B1 (ko) 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
WO2008125883A1 (fr) * 2007-04-16 2008-10-23 Cancer Research Technology Limited Marqueurs du cancer pour le pronostic et le criblage d'agents anticancéreux
EP2239580B1 (fr) * 2009-04-09 2013-03-27 Lga Biotecnologie Srl Détermination de l'efficacité du 5-ASA pour la prévention et/ou le traitement du CRC par l'analyse de l'expression génique
US20120172244A1 (en) * 2010-12-20 2012-07-05 Steven Buechler Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
TW201343920A (zh) * 2012-03-29 2013-11-01 Nat Health Research Institutes 預測前列腺癌預後之分子標記、方法與套組
US9567643B2 (en) 2013-10-04 2017-02-14 Aptose Biosciences Inc. Compositions and methods for treating cancers
US20180163271A1 (en) 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
US11149047B2 (en) 2017-10-30 2021-10-19 Aptose Biosciences, Inc. Aryl imidazoles for treatment of cancer

Patent Citations (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4230767A (en) 1978-02-08 1980-10-28 Toyo Boseki Kabushiki Kaisha Heat sealable laminated propylene polymer packaging material
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
EP0058481A1 (fr) 1981-02-16 1982-08-25 Zeneca Limited Compositions pharmaceutiques pour la libération continue de la substance active
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US5300631A (en) 1982-10-01 1994-04-05 Massachusetts Institute Of Technology Antibodies specific for either ras photo-oncogene encoded P21 proteins or ras oncogene encoded P21 proteins but not for both and method of producing same
EP0133988A2 (fr) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Préparations pharmaceutiques contenant des peptides régulateurs à libération retardée et procédé pour leur préparation
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US4762706A (en) 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US5443956A (en) 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US4720459A (en) 1985-02-14 1988-01-19 Medical College Of Wisconsin Research Foundation, Inc. Myelomas for producing human/human hybridomas
EP0239362A2 (fr) 1986-03-27 1987-09-30 Imperial Chemical Industries Plc Agents anti-tumeureux
US5081230A (en) 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US5744305A (en) 1989-06-07 1998-04-28 Affymetrix, Inc. Arrays of materials attached to a substrate
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5877305A (en) 1992-02-06 1999-03-02 Chiron Corporation DNA encoding biosynthetic binding protein for cancer marker
WO1995019970A1 (fr) 1994-01-25 1995-07-27 Warner-Lambert Company Composes tricycliques pouvant inhiber les tyrosines kinases de la famille des recepteurs du facteur de croissance epidermique
WO1995021613A1 (fr) 1994-02-09 1995-08-17 Sugen, Inc. Composes destines au traitement de troubles associes a la vasculogenese et/ou a l'angiogenese
US5473057A (en) 1994-11-09 1995-12-05 The Regents Of The University Of California Eleutherobin and analogs thereof
US5883113A (en) 1995-06-07 1999-03-16 Sugen, Inc. 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
US5792783A (en) 1995-06-07 1998-08-11 Sugen, Inc. 3-heteroaryl-2-indolinone compounds for the treatment of disease
US5886020A (en) 1995-06-07 1999-03-23 Sugen, Inc. 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
US5834504A (en) 1995-06-07 1998-11-10 Sugen, Inc. 3-(2'-halobenzylidenyl)-2-indolinone compounds for the treatment of disease
WO1997013760A1 (fr) 1995-10-11 1997-04-17 Glaxo Group Limited Composes condenses tricycliques et compositions pharmaceutiques les contenant
WO1997022596A1 (fr) 1995-12-18 1997-06-26 Zeneca Limited Derives de quinazoline
WO1997032856A1 (fr) 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1998002437A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998002434A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998014451A1 (fr) 1996-10-02 1998-04-09 Novartis Ag Derive de pyrazole condense et procede pour sa preparation
WO1998050356A1 (fr) 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
WO1998054093A1 (fr) 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
WO1999010349A1 (fr) 1997-08-22 1999-03-04 Zeneca Limited Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
WO1999024440A1 (fr) 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
WO1999035132A1 (fr) 1998-01-12 1999-07-15 Glaxo Group Limited Composes heterocycliques
WO1999035146A1 (fr) 1998-01-12 1999-07-15 Glaxo Group Limited Composes heteroaromatiques bicycliques agissant comme inhibiteurs de la tyrosine kinase
WO1999061422A1 (fr) 1998-05-29 1999-12-02 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
US20040235073A1 (en) 1999-05-19 2004-11-25 Ruppert J. Michael Kruppel-like transcriptional factor KLF4/GKLF and uses thereof
US7364868B2 (en) 1999-05-19 2008-04-29 The Uab Research Foundation Krüppel-like transcriptional factor KLF4/GKLF and uses thereof
US6534524B1 (en) 1999-07-02 2003-03-18 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
US20050196793A1 (en) 2000-03-27 2005-09-08 Waldman Scott A. Detection of CDX2 expression
US7785817B2 (en) 2000-03-27 2010-08-31 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US7479376B2 (en) 2000-03-27 2009-01-20 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
WO2001075164A2 (fr) 2000-03-30 2001-10-11 Whitehead Institute For Biomedical Research Mediateurs d'interference arn specifiques de sequences arn
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US20130177632A1 (en) * 2002-08-19 2013-07-11 Raed H. Al-Qawasmeh 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
US20070123553A1 (en) 2003-11-14 2007-05-31 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
US20050186642A1 (en) 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
WO2006126177A2 (fr) 2005-05-25 2006-11-30 Genesense Technologies Inc. Derives de 2-indolyl imidazo[4,5-d]phenanthroline et utilisation dans le traitement du cancer
US8148392B2 (en) 2005-05-25 2012-04-03 Lorus Therapeutics Inc. 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer
US20090232767A1 (en) * 2006-09-07 2009-09-17 Frankel Arthur E Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
US20110306602A1 (en) * 2007-04-24 2011-12-15 Philipp Wabnitz 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
US20100311683A1 (en) * 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
US20110171221A1 (en) 2008-04-10 2011-07-14 University Of Florida Research Foundation Compositions and methods for the treatment of a neoplasia
US20140011279A1 (en) 2008-06-27 2014-01-09 Kyoto University Method of efficiently establishing induced pluripotent stem cells
US20130034862A1 (en) 2008-07-10 2013-02-07 Nodality, Inc. Methods for Diagnosis, Prognosis and Methods of Treatment
WO2010102393A1 (fr) * 2009-03-12 2010-09-16 Lorus Therapeutics Inc. Dérivés de 2-indolylimidazo[4,5-d]phénanthroline et leur utilisation pour inhiber l'angiogenèse
US20120100131A1 (en) * 2009-04-10 2012-04-26 Kyushu University, National University Corp. Method for treatment of blood tumor using anti-tim-3 antibody
US20120251509A1 (en) 2009-10-22 2012-10-04 Waldman Scott A Cell-based anti-cancer compositions and methods of making and using the same
US20110097343A1 (en) * 2009-10-26 2011-04-28 Djordje Atanackovic Diagnosis and therapy of hematological malignancies
US20130011411A1 (en) 2010-01-06 2013-01-10 Pestell Richard G Methods and compositions for the diagnosis, prognosis, and treatment of cancer
US20110281277A1 (en) 2010-05-17 2011-11-17 Lee Ah Won Composition, kit, and method for diagnosing colorectal cancer or ovarian cancer
WO2012006032A2 (fr) * 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Traitement du cancer du sang
US20130253842A1 (en) * 2011-12-09 2013-09-26 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection

Non-Patent Citations (179)

* Cited by examiner, † Cited by third party
Title
"An interpretation of familial aggregation based on multiple genetic and environmental factors", ANN. N. Y. ACAD. SCI., vol. 91, no. 3, pages 769 - 80
"Current Protocols in Bioinformatics", 2010
"Current Protocols in Molecular Biology", 2010
"Current Protocols in Protein Science Last", 2010
"GenBank", Database accession no. ENSP00000370408
"GenBank", Database accession no. NC_000006.11
"GenBank", Database accession no. NC_000009.11
"GenBank", Database accession no. NC_000013.10
"GenBank", Database accession no. NC_018917.2
"GenBank", Database accession no. NC_018920.2
"GenBank", Database accession no. NC_018924.2
"GenBank", Database accession no. NP_001256.3
"GenBank", Database accession no. NT_007592.15
"GenBank", Database accession no. NT_008470.19
"GenBank", Database accession no. NT_024524.14
"Robbins basic pathology", 2007, SAUNDERS/ELSEVIER, pages: 12 - 8
"The Merck Manual", vol. 953, 1999
"Uniprot", Database accession no. 043474
"Uniprot", Database accession no. P38936
"Uniprot", Database accession no. Q99626
105TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION FOR CANCER-RESEARCH (AACR, 5 April 2014 (2014-04-05)
AIZU-YOKATA ET AL., CARCINOGEN, vol. 15, no. 9, 1994, pages 1875 - 1879
AKASHI ET AL., PLANTA, vol. 182, no. 3, 1990, pages 363 - 369
ALBALA ET AL.: "Protein Arrays, Biochips and Proteomics", 2003, CRC PRESS
ALLEN ET AL., AM. J. PHYSIOL., vol. 261, no. 4, 1991, pages L315 - L321
ANDO ET AL., CANCER CHEMOTHER PHARMACOL., vol. 37, 1995, pages 63 - 69
AZHAR; MURPHY, CELL MOTIL. CYTOSKELETON, vol. 15, no. 3, 1990, pages 156 - 161
BARLOW ET AL., CELL. MOTIL. CYTOSKELETON, vol. 19, no. 1, 1991, pages 9 - 17
BARLOW; CABRAL, CELL MOTIL. CYTOSKEL., vol. 19, 1991, pages 9 - 17
BHATTACHARYYA; WOLFF, BIOCHEM. BIOPHYS. RES. COMMUN., vol. 73, no. 2, 1976, pages 383 - 390
BIENVENUT: "Acceleration and Improvement of Protein Identification by Mass Spectrometry", 2005, SPRINGER
BISHOP ET AL.: "A randomized study of high-dose cytarabine in induction in acute myeloid leukemia", BLOOD, vol. 87, no. 5, 1996, pages 1710 - 7, XP002613258
BISHOP J: "The treatment of adult acute myeloid leukemia", SEMIN ONCOL, vol. 24, no. 1, 1997, pages 57 - 69
BOLLAG ET AL., CANCER RESEARCH, vol. 55, 1995, pages 2325 - 2333
BOSC ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, no. 5, 1996, pages 2125 - 2130
BOYNE ET AL., J. COMP. NEUROL, vol. 358, no. 2, 1995, pages 279 - 293
BROWN ET AL., J. CELL SCI., vol. 104, 1993, pages 339 - 352
BROWN ET AL., J. CELL. BIOL., vol. 123, no. 2, 1993, pages 387 - 403
BUCHWALD ET AL., SURGERY, vol. 88, 1980, pages 507
BULINSKI; BOSSLER, J. CELL. SCI., vol. 107, 1994, pages 2839 - 2849
BURGESS ET AL., CELL MOTIL. CYTOSKELETON, vol. 20, no. 4, 1991, pages 289 - 300
CAPLOW; SHANKS, J. BIOL. CHEM., vol. 265, no. 15, 1990, pages 8935 - 8941
CASSILETH ET AL.: "Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia", J CLIN ONCOL, vol. 6, no. 4, 1988, pages 583 - 7
COOK ET AL., MOL. BIOL. CELL, vol. 6, 1995, pages 260A
DEXTER, BR. MED. BULL., vol. 45, 1989, pages 337
DEXTER, J. CELL SCI., vol. 88, 1987, pages 1
DING ET AL., J. EXP. MED, vol. 171, no. 3, 1990, pages 715 - 727
DING ET AL., J. EXP. MED., vol. 171, no. 3, 1990, pages 715 - 727
DIRK ET AL., NEUROCHEM. RES., vol. 15, no. 11, 1990, pages 1135 - 1139
DOTTI ET AL., J. CELL SCI. SUPPL., vol. 15, 1991, pages 75 - 84
DRECHSEL; KIRSCHNER, CURR. BIOL., vol. 4, no. 12, 1994, pages 1053 - 1061
DREXLER: "Leukemia cell lines: in vitro models for the study of chronic myeloid leukemia", LEUK RES., vol. 18, no. 12, December 1994 (1994-12-01), pages 919 - 27, XP026308038, DOI: doi:10.1016/0145-2126(94)90103-1
DYE ET AL., CELL MOTIL. CYTOSKELETON, vol. 21, no. 3, 1992, pages 171 - 186
E. MAGGIO: "Enzyme-Immunoassay", 1980, CRC PRESS, INC.
ED. EGLI, MARTIN: "Current Protocols in Nucleic Acid Chemistry", 2010
ELBASHIR ET AL., NATURE, vol. 411, 2001, pages 494
ELIBASHIR ET AL., METHODS ENZYMOL., vol. 26, 2002, pages 199
EMBO J., vol. 20, 2001, pages 6877
EPSTEIN; SLEASE, SURG. ANN., vol. 17, 1985, pages 125
ESTEY E: "Treatment of acute myelogenous leukemia", ONCOLOGY, vol. 16, no. 3, pages 343 - 52,355-6
FABER ET AL.: "CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARy signaling", J CLIN INVEST.
FARRELL; KEATES, BIOCHEM. CELL. BIOL., vol. 68, no. 11, 1990, pages 1256 - 1261
FENAUX ET AL.: "A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group", BLOOD, vol. 94, no. 4, 1999, pages 1192 - 200
FERREIRA; CACERES, J. NEUROSCI., vol. 11, no. 2, 1991, pages 392 - 400
FLOREAN ET AL.: "Epigenomics of leukemia: from mechanisms to therapeutic applications", EPIGENOMICS, vol. 3, no. 5, October 2011 (2011-10-01), pages 581 - 609
FOLEY ET AL.: "Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia", CANCER, vol. 18, 1965, pages 522 - 529
FUNG: "Protein Arrays: Methods and Protocols", 2004, SPRINGER
GARCIA ET AL., ANTICAN. DRUGS, vol. 6, no. 4, 1995, pages 533 - 544
GENNARO, A.: "Remingtons Pharmaceutical Sciences''", 2000, LIPPINCOTT, WILLIAMS & WILKINS, article "Remington: The Science and Practice of Pharmacy"
GHALEB ET AL.: "Kriippel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage", ONCOGENE, vol. 26, 2007, pages 2365 - 73
GOLDE; GASSON, SCIENTIFIC AMERICAN, 1988
GOLUCH ET AL.: "Chip-based detection of protein cancer markers", PROQUEST, 2007, ISBN: 0549463453, 97805494
GONZALEZ ET AL., EXP. CELL. RES., vol. 192, no. 1, 1991, pages 10 - 15
GOODMAN S., ANN INTERN MED., vol. 130, 1999, pages 1005 - 13
GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138
GREENSTEIN ET AL.: "Characterization of the MM.l human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells", EXP HEMATOL, vol. 31, no. 4, April 2003 (2003-04-01), pages 271 - 82
HAMEL, MED RES. REV., vol. 16, no. 2, 1996, pages 207 - 231
HAMEL, MED. RES. REV., vol. 16, no. 2, 1996, pages 207 - 231
HARBORTH ET AL., J. CELL SCI., vol. 114, 2001, pages 4557
HARDWICK ET AL., J. CELL. BIOL., vol. 131, no. 3, 1995, pages 709 - 720
HASHIMOTO ET AL., ZOOL. SCI., vol. 1, 1984, pages 195 - 204
HAUSSINGER ET AL., BIOCHEM. CELL. BIOL., vol. 72, no. 1-2, 1994, pages 12 - 19
HORWITZ ET AL.: "Anticipation in familial leukemia", AM. J. HUM. GENET., vol. 59, no. 5, pages 990 - 8
HORWITZ: "The genetics of familial leukemia", LEUKEMIA, vol. 11, no. 8, pages 1347 - 59
HUANG ET AL.: "Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia", BLOOD, vol. 72, no. 2, 1988, pages 567 - 72
HUESCA ET AL., MOL CANCER THER., vol. 8, 2009, pages 2586 - 96
HWANG ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 208, no. 3, 1995, pages 1174 - 1180
IACOBUCCI ET AL.: "Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments", CURR HEMATOL MALIG REP, vol. 7, no. 2, June 2012 (2012-06-01), pages 133 - 43, XP035050028, DOI: doi:10.1007/s11899-012-0122-5
ILLINGER ET AL., BIOL. CELL, vol. 73, no. 2-3, 1991, pages 131 - 138
JAMES; LEFEBVRE, GENETICS, vol. 130, no. 2, 1992, pages 305 - 314
KIMURA ET AL.: "Antiproliferative and Antitumor Effects of Azacitidine Against the Human Myelodysplastic Syndrome Cell Line SKM-1", ANTICANCER RESEARCH, vol. 32, 2002, pages 795 - 798
LAGOS-QUINTANA ET AL., CURR. BIOL., vol. 12, 2002, pages 735
LAGOS-QUINTANA ET AL., SCIENCE, vol. 294, 2001, pages 8538
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105
LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
LENGERKE ET AL.: "BMP and Wnt specify hematopoietic fate by activation of the Cdx-Hox pathway", CELL STEM CELL, vol. 2, no. 1, 10 January 2008 (2008-01-10), pages 72 - 82, XP055072735, DOI: doi:10.1016/j.stem.2007.10.022
LEU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, no. 22, 1994, pages 10690 - 10694
LIST ET AL., J. CLIN. ONCOL., vol. 8, 1990, pages 1424
LOMBARDI ET AL.: "Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease", GENES CHROMOSOMES CANCER, vol. 46, no. 3, March 2007 (2007-03-01), pages 226 - 38
LONG; FAIRCHILD, CANCER RESEARCH, vol. 54, 1994, pages 4355 - 4361
LOPEZ ET AL., J. CELL. BIOCHEM., vol. 43, no. 3, 1990, pages 281 - 291
LUM RONNIE ET AL.: "Induction of KLF4 by LOR-253 as an innovative therapeutic approach to induce apoptosis in acute myeloid leukemia", CANCER RESEARCH, vol. 74, no. 19, October 2014 (2014-10-01), pages 4544, XP002769259, DOI: doi:10.1158/1538-7445.AM2014-4544
MALIK ET AL.: "miR-2909-mediated regulation of KLF4: a novel molecular mechanism for differentiating between B-cell and T-cell pediatric acute lymphoblastic leukemias", MOL CANCER., vol. 13, 2014, pages 175, XP021194745, DOI: doi:10.1186/1476-4598-13-175
MARGOLIS ET AL., EMBO J., vol. 9, no. 12, 1990, pages 4095 - 4102
MARTINEZ ET AL., CELL, vol. 110, 2002, pages 563
MASSON; KREIS, J. CELL BIOL., vol. 123, no. 2, 1993, pages 357 - 371
MCMANUS; SHARP, NATURE REV. GENETICS, vol. 3, 2002, pages 737
MEJILLANO ET AL., BIOCHEMISTRY, vol. 31, no. 13, 1992, pages 3478 - 3483
MESCHINI ET AL., J. MICROSC., vol. 176, 1994, pages 204 - 210
METCALF, SCIENCE, vol. 229, 1985, pages 16
MINOWADA ET AL.: "Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 49, no. 3, 1972, pages 891 - 895
MISHIMA ET AL.: "New human myelodysplastic cell line, TER-3: G-CSF specific downregulation of Ca2+/calmodulin-dependent protein kinase IV", J CELL PHYSIOL., vol. 191, no. 2, May 2002 (2002-05-01), pages 183 - 90
MITA; SHIBAOKA, PROTOPLASMA, vol. 119, no. 1/2, 1984, pages 100 - 109
MOOBERRY ET AL., CANCER LETT., vol. 96, no. 2, 1995, pages 261 - 266
MOORE, J. IND. MICROBIOL., vol. 16, no. 2, 1996, pages 134 - 143
MOORE; CYR, MOL. BIOL. CELL, vol. 7, 1996, pages 221A
NICKLAS; WARD, J. CELL BIOL., vol. 126, no. 5, 1994, pages 1241 - 1253
NILSSON ET AL.: "Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient", CLIN EXP IMMUNOL., vol. 7, no. 4, October 1970 (1970-10-01), pages 477 - 89
OGAWA, ENVIRON. HEALTH PRESP., vol. 80, 1989, pages 199
OHBA ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1158, no. 3, 1993, pages 323 - 332
OKA ET AL., CELL STRUCT. FUNCT., vol. 16, no. 2, 1991, pages 125 - 134
OOKATA ET AL., J. CELL BIOL., vol. 128, no. 5, 1995, pages 849 - 862
PANDA ET AL., J. BIOL. CHEM., vol. 272, no. 12, 1997, pages 7681 - 7687
PANDA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 10560 - 10564
PAZDUR ET AL., CANCER TREAT. REV., vol. 19, no. 4, 1993, pages 351 - 386
PIROLLET ET AL., BIOCHEMISTRY, vol. 31, no. 37, 1992, pages 8849 - 8855
PIROLLET ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1160, no. 1, 1992, pages 113 - 119
QAYYUM ET AL.: "Adult T-cell leukemia/lymphoma", ARCH PATHOL LAB MED, vol. 138, no. 2, February 2014 (2014-02-01), pages 282 - 6
RAYNAUD ET AL., CANCER CHEMOTHER PHARMACOL., vol. 35, 1994, pages 169 - 173
RINGEL; HORWITZ, J. NATL. CANCER INST., vol. 83, no. 4, 1991, pages 288 - 291
ROB GOLDMAN, LORUS THERAPEUTICS, INC.THE NEXT MAJOR ONCOLOGY PLAYER, 9 October 2012 (2012-10-09), pages 1 - 13
ROUHI ET AL.: "Deregulation of the CDX2-KLF4 axis in acute myeloid leukemia and colon cancer", ONCOTARGET, vol. 4, no. 2, February 2013 (2013-02-01), pages 174 - 175
ROWLAND ET AL.: "KLF4, p21 and context-dependent opposing forces in cancer", NAT REV CANCER, vol. 6, no. 1, January 2006 (2006-01-01), pages 11 - 23
ROWLAND ET AL.: "The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene", NAT CELL BIOL., vol. 7, 2005, pages 1074 - 82
SAANDI ET AL.: "Regulation of the tumor suppressor homeogene Cdx2 by HNF4a in intestinal cancer", ONCOGENE, vol. 32, no. 32, 8 August 2013 (2013-08-08), pages 3782 - 8
SAFIEJKO-MROCZKA; BELL, J. HISTOCHEM. CYTOCHEM., vol. 44, no. 6, 1996, pages 641 - 656
SAKOWICZ ET AL., SCIENCE, vol. 280, 1998, pages 292 - 295
SAMBROOK, JOSEPH: "Molecular Cloning: A Laboratory Manual", 2001
SAOUDI ET AL., J. CELL SCI., vol. 108, 1995, pages 357 - 367
SAOUDI ET AL., J. CELL. SCI., vol. 108, 1995, pages 357 - 367
SAOUDI ET AL., J. CELL. SCI., vol. 108, pages 357 - 367,1995
SAUDEK ET AL., N. ENGL. J. MED., vol. 321, 1989, pages 574
SCHIFF ET AL., NATURE, vol. 277, 1979, pages 665 - 667
SCHILSTRA ET AL., BIOCHEM. J., vol. 277, 1991, pages 839 - 847
SCHNEIDER ET AL.: "Characterization of EBV-genome negative ''null'' and ''T'' cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma", INT J CANCER., vol. 19, no. 5, 15 May 1977 (1977-05-15), pages 621 - 6
SCHOENHALS ET AL.: "Kruppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma", HAEMATOLOGICA, vol. 98, 2013, pages 1442 - 9
SCHOLL ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 17, no. 4, pages 1037 - 1048
SCHOLL ET AL.: "The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis", J. CLIN. INVEST., vol. 117, 2007, pages 1037 - 1048
See also references of EP3052102A4
SEFTON, CRC CRIT. REF. BIOMED. ENG., vol. 14, 1987, pages 201
SHERO ET AL., GENES DEV., vol. 5, no. 4, 1991, pages 549 - 560
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556
SIMERLY ET AL., J. CELL BIOL., vol. 111, no. 4, 1990, pages 1491 - 1504
SOLLOTT ET AL., J. CLIN. INVEST., vol. 95, 1995, pages 1869 - 1876
SONG ET AL., J. CELL. SCI. SUPPL., vol. 14, 1991, pages 147 - 150
SPEICHER: "Proteome Analysis: Interpreting the Genome", 2004, ELSEVIER
STARGELL ET AL., MOL. CELL. BIOL., vol. 12, no. 4, 1992, pages 1443 - 1450
TABBARA; ROBINSON, ANTI-CANCER RES., vol. 11, 1991, pages 81
TALLMAN ET AL.: "All-trans-retinoic acid in acute promyelocytic leukemia", N. ENGL. J. MED., vol. 337, no. 15, 1997, pages 1021 - 8
TAYLOR ET AL.: "In Henderson ES", WB SAUNDERS, article "The hereditary basis of human leukemia", pages: 210
TER HAAR ET AL., BIOCHEMISTRY, vol. 35, 1996, pages 243 - 250
THURSTON ET AL., CHROMOSOMA, vol. 105, no. 1, 1996, pages 20 - 30
TOHYAMA ET AL.: "A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages", BR J HAEMATOL., vol. 91, no. 4, December 1995 (1995-12-01), pages 795 - 9
TSCHESCHE: "Methods in Protein Biochemistry", 2011, WALTER DE GRUYTER
TUSCHL ET AL., NATURE BIOTECHNOL., vol. 20, 2002, pages 446
TUSCHL, CHEMBIOCHEM, vol. 2, 2001, pages 239
VAN DOLAH; RAMSDELL, J. CELL. PHYSIOL., vol. 166, no. 1, 1996, pages 49 - 56
WALKER ET AL., J. CELL BIOL., vol. 114, no. 1, 1991, pages 73 - 81
WALKER: "The Protein Protocols Handbook", 2002, SPRINGER
WANG ET AL., BRAIN RES. MOL. BRAIN RES., vol. 38, no. 2, 1996, pages 200 - 208
WANG ET AL.: "siRNA targeting of Cdx2 inhibits growth of human gastric cancer MGC-803 cells", WORLD J GASTROENTEROL., vol. 18, no. 16, 28 April 2012 (2012-04-28), pages 1903 - 1914
WEICK ET AL.: "A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study'' (PDF", BLOOD, vol. 88, no. 8, 1996, pages 2841 - 51
WEIMER ET AL., J. CELL. BIOL., vol. 136, no. 1, 1997, pages 71 - 80
WIEMER ET AL., J. CELL. BIOL., vol. 136, no. 1, 1997, pages 71 - 80
WIRTH, U. ET AL., PROTEOMICS, vol. 2, no. 10, 2002, pages 1445 - 51
WOOD ET AL., MOL. PHARMACOL., vol. 52, no. 3, 1997, pages 437 - 444
YONETANI ET AL., MOL. BIOL. CELL, vol. 7, 1996, pages 211A
YOON ET AL.: "Kriippel-like Factor 4 Mediates p53-dependent Gl/S Cell Cycle Arrest", RESPONSE TO DNA DAMAGE, vol. 278, no. 4, 24 January 2003 (2003-01-24), pages 2101 - 2105

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10080739B2 (en) 2003-11-14 2018-09-25 Aptose Biosciences Inc. Aryl imidazoles and their use as anti-cancer agents
US11104957B2 (en) 2013-10-04 2021-08-31 Aptose Biosciences, Inc. Compositions and methods for treating cancers
US11149047B2 (en) 2017-10-30 2021-10-19 Aptose Biosciences, Inc. Aryl imidazoles for treatment of cancer

Also Published As

Publication number Publication date
EP3052102A4 (fr) 2017-05-31
EP3052102B1 (fr) 2019-12-04
JP6946000B2 (ja) 2021-10-06
HK1225647A1 (zh) 2017-09-15
CN105764511B (zh) 2019-01-11
KR20160058960A (ko) 2016-05-25
WO2015051304A1 (fr) 2015-04-09
JP2021121632A (ja) 2021-08-26
US20170335400A1 (en) 2017-11-23
JP2019218373A (ja) 2019-12-26
US20150104392A1 (en) 2015-04-16
JP2016531885A (ja) 2016-10-13
US20190062842A1 (en) 2019-02-28
DK3052102T3 (da) 2020-03-09
ES2775579T3 (es) 2020-07-27
EP3650023A1 (fr) 2020-05-13
US9567643B2 (en) 2017-02-14
EP3052102A1 (fr) 2016-08-10
CN105764511A (zh) 2016-07-13
US11104957B2 (en) 2021-08-31
US20150099775A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
US11104957B2 (en) Compositions and methods for treating cancers
US11473151B2 (en) Diagnostic and therapeutic methods for cancer
US20220153861A1 (en) Therapeutic and diagnostic methods for cancer
JP2023159152A (ja) がんを治療するための組成物及び方法
AU2017339517A1 (en) Therapeutic and diagnostic methods for cancer
JP2020138972A (ja) 疾患および障害の処置においてレナラーゼを制御する組成物および方法
US20210253710A1 (en) Diagnostic and therapeutic methods for kidney cancer
JP7319688B2 (ja) 長鎖ノンコーディングｒｎａを標的とするがん治療剤およびがん診断方法
CN113521069A (zh) 用于治疗癌症的mdm2抑制剂的给药方案
RU2677656C2 (ru) Способ прогнозирования терапевтического эффекта для пациента с колоректальным раком, у которого повышена экспрессия белка tk1
JP2020534322A (ja) 薬剤耐性神経膠腫の治療法
JP2013049646A (ja) 癌治療剤
KR20190052255A (ko) Idf-11774 및 자가용해소체 형성 저해제를 포함하는 암의 예방 또는 치료용 조성물
CN105189786A (zh) 用作治疗癌症的疗法的靶标的falz
US20200031920A1 (en) Combination Therapy for Treating Cancer
WO2022031859A2 (fr) Acide méthylmalonique et son métabolisme en tant que biomarqueur du cancer et cible
WO2023008533A1 (fr) Composition pharmaceutique destinée au traitement du cancer du pancréas et du cancer du canal cholédoque
Roger et al. Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma
KR20240055944A (ko) 치료 유도 노화 세포 사멸용 조성물 및 이의 용도
CN117045788A (zh) Pes1抑制剂在食管鳞状细胞癌免疫治疗中的应用
WO2018222831A1 (fr) Ciblage de la lysine déméthylase (kdms) en tant que stratégie thérapeutique destinée au lymphome diffus à grandes cellules b
BR112017018775B1 (pt) Métodos e composições para previsão da eficácia terapêutica dos tratamentos e prognósticos de câncer
TW200831111A (en) Compositions including triciribine and anthracyclin analogs and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14850583

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016519769

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014850583

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014850583

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20167011859

Country of ref document: KR

Kind code of ref document: A